WO2009113065A1 - Compositions immunomodulatrices pour le traitement de troubles d’origine immunologique - Google Patents

Compositions immunomodulatrices pour le traitement de troubles d’origine immunologique Download PDF

Info

Publication number
WO2009113065A1
WO2009113065A1 PCT/IL2009/000273 IL2009000273W WO2009113065A1 WO 2009113065 A1 WO2009113065 A1 WO 2009113065A1 IL 2009000273 W IL2009000273 W IL 2009000273W WO 2009113065 A1 WO2009113065 A1 WO 2009113065A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
disorder
colostrum
immune
regulatory
Prior art date
Application number
PCT/IL2009/000273
Other languages
English (en)
Inventor
Yaron Ilan
Gad Lalazar
Ami Ben-Yaakov
Tomer Adar
Original Assignee
Hadasit Medical Research Services & Development Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services & Development Ltd. filed Critical Hadasit Medical Research Services & Development Ltd.
Priority to AU2009222965A priority Critical patent/AU2009222965B2/en
Priority to CA2718381A priority patent/CA2718381A1/fr
Priority to NZ587901A priority patent/NZ587901A/xx
Priority to EP09720973.8A priority patent/EP2268669B1/fr
Priority to DK09720973.8T priority patent/DK2268669T3/da
Publication of WO2009113065A1 publication Critical patent/WO2009113065A1/fr
Priority to US12/879,129 priority patent/US20110200610A1/en
Priority to US13/715,371 priority patent/US20130164302A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Definitions

  • the invention relates to an imniuno-niodulating composition for the treatment and prophylaxis of an immune-related disorder. More specifically, the invention relates to immunomodulatory compositions comprising mammalian colostrum -derived immunoglobulin preparation and optionally further colostrums, milk or milk product component/s and any adjuvants for treating immune-related disorders. The invention further provides methods and uses of the immunomodulatory compositions for an active or passive immunization in a disease-antigen specific or non specific manner.
  • tumors in vivo have generally not been found to be very immunogenic and in many instances appear to be capable of evading the body's immune response.
  • Today a great deal of anti-cancer work is directed at finding ways of increasing the immunogenicity of a tumor cell in vivo, by modulating and preferably, stimulating the subject's immune response against the cancer.
  • Many studies have attempted use of IgG as passive immunity or stimulation of natural IgG production to restrict tumor growth.
  • Colostrum also known as first milk
  • first milk is a form of milk produced by the mammary glands in late pregnancy and the few days after birth. In humans it has high concentrations of nutrients and antibodies, but is small in quantity. Colostrum is high in carbohydrates, protein, mineral salts, vitamins and immunoglobulin. It also contains various floating cells such as granular and stromal cells, neutrophils, monocyte/macrophages and lymphocytes and includes growth factors, hormones and cytokines.
  • Leukocytes are also present in colostrum in large numbers which enable protection against viruses and bacteria.
  • Colostral leukocytes enhance passive immunity of neonatal calf, especially in regard to antibodies and immunoglobulin classes which are essential for intestinal immunity.
  • Bovine colostrum contains three major classes of immunoglobulins: IgG, IgM and IgA.
  • colostrum is quite a unique product that arises from a distinct physiological and functional state of the mammary gland.
  • the principal compositional difference between colostrum and mature milk is the very high content of bioactive components such as lactoferrin and immunoglobulins [Tarbell, KV. et al. J. Exp. Med. 199:1467-77 (2004); Bluestone, J.A. and Tang, Q. J. Autoimmun 24:55-62 (2005); Putnam, A.I. et al J.Autoimmun. 24:55-62 (2005)], of which IgG class makes up 80-90%.
  • Colostrum further comprises chemotactic activators of the immune system known as alarmins.
  • the mechanisms by which multicellular organisms respond to infections and tissue injury, as well as restore tissue homeostasis are known as "the inflammatory response”.
  • the initiation of an appropriate inflammatory response requires the recognition of exogenous as well as endogenous danger signals- molecules that alert the innate immune system and trigger defensive immune responses.
  • Endogenous molecules which initiate inflammatory responses by interaction with signaling receptors are known as endokines and/or alarmins.
  • potent immunostimulants are rapidly released following pathogen challenge and/or cell death, recruit and activate antigen- presenting cells which are critical for mounting an immune response, and include defensins, cathelicidin, eosinophil-derived neurotoxin, and high- mobility group box protein 1 (HMGBl).
  • defensins include defensins, cathelicidin, eosinophil-derived neurotoxin, and high- mobility group box protein 1 (HMGBl).
  • HMGBl high- mobility group box protein 1
  • the immunization of an animal such as a cow with specific antigens enables the production and harvest of specific antibodies that may be used for modulation of an immune response and thereby in the treatment of immune-related disorders. Accordingly, this method serves as an easy and safe means for generating antigen-specific antibodies and immune adjuvants.
  • ANADIS LTD. Several previous patents and patent applications by part of the present inventors (ANADIS LTD.), described the use of specific bacterial pathogens antibodies,, obtained from bovine colostrum for the passive treatment of infectious diseases.
  • WO 04/078209 by part of the present inventors describes compounds and compositions for treatment or prophylaxis of gastrointestinal disorders prepared by immunizing a host animal with a vaccine comprising one or more cell wall antigens of enteric bacteria, specifically, gram negative bacteria.
  • the hyper immune material produced is in the form of tablets for oral administration.
  • WO 03/097094 describes the use of a hyper immune colostrum in the production of antibodies (whole IgG), or F(ab')2 antibodies fragments, conjugated with mammalian colostrums and colostrums extracts, for intranasal administration aimed at the prevention of symptoms arising from the presence of air-borne pathogenic bacteria.
  • WO 95/08562 by part of the inventors, describes the method of obtaining high purity immunoglobulins from antibody rich colostrum and the possibility of compressing these colostral-antibodies into a tablet form without substantial loss of activity.
  • Specific antibodies are obtained by immunization of a mammal with specific antigens against enterotoxic bacteria such as E. coli, Salmonela and Shigella.
  • WO 06/053383 by part of the inventors, describes a carboxylic acid and alkalizing moieties which confer upon a bioactive agent composition of a hyper immune colostrum, lactoferrin or lactoferracin, stability under a wide variety of gastric pH values
  • WO 03/080082 by part of the inventors, describes a method of improving the viability of a labile bioactive substance, preferably immunoglobulins or fragments thereof or enzymes, in a gastric environment, comprising forming a mixture of the bioactive substance and mammalian colostrum and colostrums extracts. This conjugation protects the antibodies or antibodies fragments from the proteolysis occasioned by enzyme or low pH conditions and preserve their function in the stomach or rumen or other hostile environment.
  • Tregs Regulatory T cells are specialized subpopulation of T cells that act to suppress activation of the immune system and thereby maintain immune system homeostasis and tolerance to self- antigens, and limit chronic inflammatory diseases [Vignali, D. A. et al. Nat. Rev. Immunol. 8:523-32 (2008)]. Induction of Tregs is accepted as a main pathway for immunotherapy in immune mediated disorders [Lopez-Diego, R. S. and Weiner, H.L. Nat. Rev. Drug Discov. 7:909-25 (2008)]. Tregs promotion occurs without systemic immuno-suppression, making this intervention safe and with a low rate of side effects.
  • CD 3 -specific antibodies were recently shown to exert an immune modulatory effect by promoting Tregs, and specifically, CD4+CD25-LAP+ Tregs, which function in vitro and in vivo through a TGF- ⁇ -dependent mechanism [Ochi, H. et al. Nat. Med. 12:627-35 (2006)].
  • monoclonal anti-CD3 antibodies by inducing Tregs, suppress experimental allergic encephalomyelitis, diabetes and lupus [Ochi (2006) ibid. Wu, H.Y. et al. J. Immunol 181:6038-50 (2008); Chen, M.L. Y.et al. J. Immunol. 180:7327-37 (2008); Ishikawa, H.
  • CD4+ T cells stimulated with anti-CD3 markedly suppressed the proliferation and cytokine production of autologous peripheral blood monocytes [Abraham, M. et al. J. Autoimmun. 30:21-8 (2008)].
  • These Tregs were not induced by incubation with isotype control antibody or by a combination of anti-CD3 with high doses of anti-CD28.
  • Tregs are type 1 diabetes mellitus
  • TlDM type 1 diabetes mellitus
  • Tregs act as bystander suppressors of heterologous auto reactive immune responses [Homann, D. et al. J. Immunol. 163:1833-8 (1999); Homann, D. et al. Immunity 11:463- 72 (1999)].
  • the combination therapy increased the level of CD4+CD25+Foxp3+ Tregs and enhanced their proinsulin-specific IL-IO, IL-4, and TGF- ⁇ production.
  • combination therapy suppresses auto-aggressive CD8 responses [Bresson, D. et al. J. Clin. Invest. 116:1371-81 (2006)].
  • combination therapy with anti-CD 3 expands islet-specific Tregs more forcefully.
  • T2DM type 2 diabetes mellitus
  • T2DM type 2 diabetes mellitus
  • macrophages and the endothelium contribute to increased serum levels of different cytokines including IL-l ⁇ , IL-6, and TNF in T2DM patients [Pickup, J.C. and Crook, M.A.
  • Diabetologia 41:1241-8 (1998)].
  • the metabolic syndrome is currently recognized as a pro-inflammatory and prothrombotic condition, with increased C-reactive protein (CRP) and interleukin (IL)-6 [Ruth, M.R. and Proctor, S.D. Int. J. Obes. (Lond) 33:96- 103 (2009); Dandona, P. et al. Trends Immunol. 25:4-7 (2004); Hotamisligil, G.S. Int. J. Obes. Relat. Metab. Disord. 27 Suppl 3:S53-5 (2003)].
  • CRP C-reactive protein
  • IL-6 interleukin-6
  • Adipose tissue is increasingly recognized as a metabolically active endocrine organ with multiple functions beyond its lipid storage capability [Permana, P.A. et al. Methods MoI. Biol. 456:141-54 (2008)].
  • Adipose tissue has an. active role in the development and maintenance of insulin resistance. In obese individuals, adipose tissue releases increased amounts of non-esterified fatty acids, glycerol, hormones, pro-inflammatory cytokines and other factors that are involved in the development of insulin resistance [Hotamisligil, G.S. Nature 444:860-7 (2006); Kahn, S.E. et al. Nature 444:840-6 (2006)].
  • beta-cell function is therefore critical in defining the risk and development of type 2 diabetes.
  • a crosstalk between lymphocytes and adipocytes was suggested important in this setting [Poggi, M. et al. Diabetologia (2Q09)].
  • adipokines Various constituents of the adipose tissue, such as mature adipocytes and stromal vascular cells, have distinct functions [Permana (2008) ibid.]. They express and secrete different kinds of bioactive molecules collectively called adipokines. Altered adipokine secretion patterns characterize obesity and insulin resistance, which are major risk factors for type 2 diabetes mellitus.
  • Tregs have been associated with type 1 diabetes mellitus (TlDM) [Yan, Y. et al. Int. J. Immunopathol. Pharmacol. 21:767-80 (2008); Lazarski, CA. Immunity 29:511-512 (2008); Manirarora, J.N. et al. PLoS ONE 3:e3739 (2008); Lawson, J.M. et al. Clin. Exp. Immunol. 154:353-9 (2008)] and with the development of type 2 diabetes mellitus (T2DM) [Sharif, S. et al. Ann. N.Y. Acad. Sci. 958:77-88 (2002)].
  • T2DM type 2 diabetes mellitus
  • CD4+CD25+ Tregs were shown to modulate the activity of the insulin receptor in an animal model of T2DM [Zhao, H. et al. Diabetes 56:1210-8 (2007)].
  • exercise-induced-increase in CD4+CD25+ Tregs correlated with decreased hemoglobin AlC serum levels [Zhao (2007) ibid.].
  • the present invention now demonstrate the use of mammalian colostrum- derived immunoglobulin preparations as immuno-modulators capable of modulating immune-regulatory cells, specifically, regulatory T cells. Such modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance, which governs the immune response.
  • these effects upon the immune system enable the use of such colostrums-derived preparations for the treatment of immune-related disorders in an active, as well as passive manner.
  • these immuno-globulin preparations and compositions thereof may be directed to antigens specific for a certain immune-related disorders or alternatively, may modulate the immune- response in a disease non-specific manner by inducing specific cells or parts of the immune system in a non specific way, including an immune bystander effect, or non disease target antigen.
  • WO 2005/048935 describes the immunomodulatory effect of an anti CD 3 antibody on autoimmune disorders. More specifically, this publication shows that oral and mucosal administration of anti-CD 3 antibody suppresses experimental allergic encephalomyelitis (EAE), delays allograft rejection in a dose-dependent fashion, reduces the severity of arthritis and prevents the onset of diabetes in NOD mouse model.
  • EAE experimental allergic encephalomyelitis
  • the colostrum- derived immunoglobulin preparations of the present invention are directed towards antigens derived from samples obtained from diseased subjects, or disease-related antigens, (such as insulin, for treating diabetes type 2), and therefore activate regulatory T cells specific for a certain disease.
  • disease-related antigens such as insulin, for treating diabetes type 2
  • the colostrum-derived immunoglobulin preparation of the invention may provide specific and optionally, tailored compositions for efficient treatment of a certain immune-related disorder, by an active manner as mediated by regulatory T cells.
  • immunomodulatory compositions comprising colostrum-derived immunoglobulin preparation, and uses thereof in methods of preventing and/or treating immune-related disorders, specifically, Metabolic Syndrome, autoimmune disorders, malignant and non-malignant proliferative disorder, genetic disease, infectious diseases and neurodegenerative disorders.
  • the invention relates to an immuno- modulating composition for the treatment and prophylaxis of an immune-related disorder. More specifically, such composition comprises as an active ingredient mammalian colostrum-derived, milk or milk products-derived immunoglobulin preparation and optionally further colostrums, milk or milk products component/s and any adjuvant.
  • the immunoglobulin preparation of the invention or any fragments thereof is capable of recognizing and binding at least one antigen specific for the disorder and modulating immune-regulatory cells, specifically, regulatory T cells. Such modulation may lead for example, to modulation of the Thl/Th2, Trl/Th3 cell balance thereby activating or inhibiting an immune response specifically directed toward said disorder.
  • this immuno-modulatory effect may be mediated by activation or promotion of specific subsets of regulatory cells, or antigen presenting cells, via direct or indirect activation.
  • the colostrum- derived immuno -globulin preparation of the invention may act in an antigen specific and non specific manner, by working against bystander antigens, or by being directed towards non associated antigens.
  • the immunoglobulin preparation of the invention may be directed to antigens that are not specific to the treated disorder.
  • antigens may be any target immune- related components having a modulatory effect on the immune-response.
  • recognition of such disease non-specific antigens by the immunoglobulin preparation of the invention may results in alteration of the immune-response.
  • the invention relates to the use of mammalian colostrum-derived, milk or milk products-derived immunoglobulin preparation in an active or passive manner, for preparing an immuno-modulating composition for the treatment and prophylaxis of an immune-related disorder.
  • the immunoglobulin preparation used by the invention may recognize and bind at least one antigen specific for said disorder and modulate immune-regulatory cells, specifically, regulatory T cells.
  • the immunoglobulin preparation of the invention may be directed to antigens that are not specific to the treated disorder.
  • the immunoglobulin preparation of the invention may target component of the immune-system, having an immunomodulatory effect, thereby binding to such component may modulate the immune-response. Such modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance thereby activating or inhibiting an immune response specifically directed toward said disorder.
  • the invention relates to a method for the treatment and prophylaxis of an immune-related disorder.
  • the method of the invention comprises the step of administering to a subject in need thereof a therapeutically effective amount of mammalian colostrum- derived, milk or milk products-derived immunoglobulin, preparation or of a composition comprising the same.
  • the immunoglobulin preparation or any fragments thereof, used by the method of the invention recognize and bind at least one antigen specific for such disorder and thereby modulate regulatory T cells leading to modulation of the Thl/Th2, Trl/Th3 cell balance.
  • the immunoglobulin preparation of the invention may be directed towards an immuno-modulatory component that may not be specific to the certain treated disorder. Modulation of the Thl/Th2, Trl/Th3 cell balance may activate or alternatively, inhibit an immune response in the treated subject.
  • the invention provides an immuno- modulatory combined composition comprising as an active ingredient a combination or mixture of colostrum preparation and immunomodulatory therapeutic agent.
  • Figure 1A-1B Effect of oral administration of colostrum-enriched antibodies on regulatory T cells distribution
  • CD4+CD25+FoxP3+ CD4+CD25+FoxP3+IL17+, CD8+CD25+, and
  • Fig. IB The ratio of Tregs determined by the FACS analysis for group D versus control group G was calculated for the four types of Tregs
  • CD4+CD25+FoxP3+ CD4+CD25+FoxP3+ILl7+, CD8+CD25+, and
  • AT anterior sarcoma
  • SV stromal vasculature
  • SP spleen
  • Figure 2A-2D Effect of oral administration of colostrum-enriched antibodies on insulin resistance
  • Fig 2A Mice treated with anti insulin antibodies in low and high doses (groups A and B, respectively), mice fed with purified anti insulin antibodies (groups C and D, respectively), and untreated mice (group G) underwent glucose tolerance test. The decrease was significant for group A-D versus G (p ⁇ 0.005)
  • Fig 2B Levels of fasting serum insulin were teased in mice of groups A-E and G following four weeks of feeding. The decrease was significant for group A-C versus G (p ⁇ 0.005)
  • Fig 2C Levels of fasting serum glucose were measured in the mice from groups A-E and G on a weekly basis, and the mean decrease over four weeks of treatment was calculated. The mean decrease was significantly higher for mice in groups A and B, vs. C-E and G (p ⁇ 0.005).
  • Fig 2D The decrease in fasting serum glucose levels in mice from groups A-E and G per week is shown. A significantly higher decrease was noted throughout the study from mice in group B versus all other groups (p ⁇ 0.005), and for mice in group A versus C, D, E and G on weeks 1, 3 and 4 (p ⁇ .005).
  • D days
  • W weeks
  • GIu glucose
  • Ser ser (serum), Ins (insulin), Dec (decrease).
  • Liver triglyceride content was calculated at the end of the study on all treated and control groups. The decrease was significant for group A -F vs. G (p ⁇ 0.005), and for group A and B vs. C, D, E, and F (P ⁇ 0.001). Abbreviations: Li (liver), TG (triglycerides).
  • Figure 4A-4B Effect of oral administration of colostrum-enriched antibodies on body weight and liver weight
  • Fig 4A Body and liver of mice from groups A-D and G were weighed at the end of the study. No significant differences were noted between the groups.
  • Fig 4B Body vs. liver weight ratio was calculated for each group at the end of the study. No significant differences were noted between the different groups.
  • LI liver
  • BO body
  • RA ratio
  • a productive immune response results from the effective integration of positive and negative signals that have an impact on both innate and adaptive immune cells.
  • positive signals dominate, cell activation and pro-inflammatory responses ensue, resulting in the elimination of pathogenic microorganisms, viruses as well a transformed cell.
  • cell activation is blocked and active anti-inflammatory responses can occur.
  • Modulation of this binary system occurs through the action of cytokines, downstream signaling pathways and cell-cell contact. The perturbation of these thresholds can result in aberrant responses that are either insufficient to deal with pathogenic microorganisms or result in the loss of tolerance and the induction of autoimmune responses.
  • the present invention shows an immunomodulatory effect of a colostrum-derived immunoglobulin preparation that may act in an active manner for the treatment of immune-related disorders.
  • Tregs are increasingly recognized as an important immunomodulatory component of the adaptive immune system. Immune dysregulation may lead to chronic inflammation as a trigger for chronic insulin insensitivity.
  • the present invention shows in a particular example, that oral administration of colostrum-derived anti insulin antibodies promote Tregs in adipose tissue and in adipose tissue associated stromal vasculature. These alterations are associated with alleviation of the Metabolic Syndrome and the associated liver injury in the ob/ob mice model. Therefore, the present invention provides as a novel therapeutic composition for the alleviation and treatment of the Metabolic Syndrome. Previous studies have shown that feeding of non specific antibodies, anti- CD 3, is an effective method for the induction of Tregs [Ochi (2006) ibid.
  • the data provided herein shows for the first time that the use of antigen specific antibodies can induce Tregs in an organ specific manner.
  • the invention shows that feeding of anti insulin antibodies promoted Tregs in the adipose tissue and SV (stromal- vascular cells). Both, CD4+CD25+FoxP3+ and CD8+CD25+FoxP3+ lymphocyte subsets are promoted in these organs.
  • Tregs were previously suggested to play a role in diabetes [Bresson, D. et al. J. Clin. Invest. 116:1371-81 (2006), Wang, R. Immunology 126:123-31 (2009), Tarbell, KV. et al. J. Exp. Med. 199:1467-77 (2004); Bluestone (2005) ibid.; Putnam (2005) ibid.; James (2007) ibid.], adipose tissue and SV- derived cells were not previously described to be associated with alleviation of the Metabolic Syndrome.
  • adipokines altered adipokine secretion patterns characterize obesity and insulin resistance, which are major risk factors for type 2 diabetes mellitus. Regional and genotypic differences are present in stromal-vascular cells from obese and lean Zucker rats [Turkenkopf, I. J. et al. Int. J. Obes. 12:515-24 (1988)].
  • the invention further shows that the promotion of Tregs in the adipose tissue and SV by administration of anti insulin antibodies is associated with insulin resistance alleviation. This is demonstrated by glucose levels and glucose tolerance tests, indicating a decrease both in gluconepgensis (decreased fasting glucose) and in insulin resistance (reduced GTT values and AUC).
  • the inflammatory liver damage is alleviated by the present invention, as manifested by a decrease in liver enzymes, and hepatic fat accumulation.
  • the invention shows that oral administration of colostrum-enriched with anti insulin antibodies can serve as a mean to promote Tregs in the adipose tissue and the adipose tissue associated stromal vasculature.
  • Colostrum-derived exosomes inhibit anti-CD3-induced IL-2 and IFN-gamma production from allogeneic and autologous PBMC [Nagatomo, T. et al. Clin. Exp. Immunol. 138:47-53 (2004); Admyre, C. et al. J. Immunol.
  • CD25 expression in PBMC was enhanced by pretreatment with colostrum derived IL- l ⁇ , TNF- ⁇ and IFN- ⁇ [Harlan, D.M. and Von Herrath, M. Nat. Med. 11:716-8 (2005)].
  • Oral administration of bovine colostrum (BC) can also affect the local immunity in the intestine altering the T cell polarization.
  • the CD21+/CD3+ cells populations of the ileal Peyer's patch (iPP) are markedly affected by BC. Exposure to BC increased the percentage of cells expressing CDlIa, CDlIc and CD43, but decreased the percentage of cells expressing CD62L relative to freshly isolated PBMC, facilitating lymphocyte trafficking.
  • the present invention shows that the specificity of the antibody fed is essential for Treg accumulation.
  • Administration of non anti specific antibodies enriched colostrum derived solution (NAIS-CDS), containing anti E. coli antibodies proved to be less efficient than anti insulin antibodies in promotion of Tregs in adipose tissue and SV, and as a result less efficient in improving insulin resistance.
  • NAIS-CDS non anti specific antibodies enriched colostrum derived solution
  • the invention also presents the additive value of the colostrums-derived adjuvants by its effect on the distribution of Tregs, and by a more profound effect noted on fasting glucose and insulin levels.
  • Several proteins were identified in breast milk as involved in host defense [Kahn, S. E. et al. Nature 444:840-6 (2006)], including high concentrations mediators of the innate immune system [Poggi, M. et al. Diabetologia (2009)].
  • mediators are multiple defensin proteins, sphingolipids, osteopontin, exosomes, TLRs, cathelicidin, ⁇ eosinophil- derived neurotoxin, and high-mobility group box protein 1, and LL-37 [Poggi (2009) ibid.; Nagatomo, T. et al. Clin. Exp. Immunol. 138:47-53 (2004); Admyre, C. et al. J. Immunol. 179:1969-78 (2007); Oppenheim, J. J. and Yang, D. Curr. Opin. Immunol. 17:359-65 (2005)]. These can activate the innate and adaptive immune systems.
  • Induction of antigen-specific Treg may result in a long-lasting tolerance to ⁇ cell antigens, mediated by local immune modulation in the pancreatic draining lymph nodes (PLNs) [Homann, D. et al. J. Immunol. 163:1833-8 (1999); Homann, D. et al. Immunity 11:463-72 (1999)].
  • PPNs pancreatic draining lymph nodes
  • This intervention has shown great promise in animal models, but has had little efficacy in human trials.
  • In the Diabetes Prevention Trial only a sub-fraction of treated patients showed a beneficial effect with immunization with islet autoantigens [Skyler, J.S. et al. Diabetes Care 28:1068-76 (2005)].
  • the invention showed a dose dependent effect on the intestine mucosal immune system, similar to that described in other systems of oral tolerance [Faria, A.M. and Weiner, ELL. Glin. Dev. Immunol. 13:143-57 (2006)].
  • the effect on Treg distribution and insulin resistance parameters was different between mice administered high and low doses of the anti insulin antibodies, the data suggests that different dosing may determine the effect on subsets of Tregs promoted, and on the associated clinical effect.
  • the invention clearly demonstrate that antigen specific antibodies together with colostrum adjuvants can promote Tregs accumulation, and thereby serve as means for alleviating inflammatory response and improving Metabolic Syndrome complications. Further, according to the invention, Regulatory T lymphocytes in the adipose tissue and the SV can serve as a new therapeutic target in Metabolic Syndrome patients. Moreover, the immunoglobulins in the colostrum may promote regulatory T cells or any other cell related to the immune system in an antigen specific and non specific way, by targeting bystander antigens, or by being directed against non associated antigens.
  • the invention relates to an immuno-modulating composition for the treatment and prophylaxis of an immune-related disorder. More specifically, such composition comprises as an active ingredient, mammalian colostrum-derived, milk or milk-product-derived immunoglobulin preparation and optionally further colostrums, milk or milk-product component/s. It should be noted that the colostrum-derived composition of the invention may further comprises any added adjuvant.
  • the immunoglobulin preparation of the invention or any fragments thereof may be capable of recognizing and binding at least one antigen specific for the disorder and modulating immune-regulatory cells, specifically, regulatory T cells.
  • Such modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance thereby activating or inhibiting an immune response specifically directed toward said disorder.
  • the colostrums-derived immunoglobulin preparation of the invention or the immuno- modulatory composition derived therefrom may act in an indirect manner by activation or promotion of specific subsets of regulatory cells, or antigen presenting cells, or by any type of cell-cell contact.
  • Such immunoglobulin preparation may be directed towards different components of the immune-system. For example, activation of specific regulatory T cells, B cells or antigen presenting cells, or any other cells that associated with an effect on the immune system, or induces the secretion of cytokines or chemokines or affects the immune system in any other way.
  • Alteration or promotion of immune cells may further involve induction of any type of regulatory cells, preferably, regulatory T cells, for example, Th3 cells, TrI, T17 cells or any other type of regulatory, effector or suppressor cells.
  • regulatory T cells for example, Th3 cells, TrI, T17 cells or any other type of regulatory, effector or suppressor cells.
  • ThI 7 cells are a recently-identified subset of CD4 + T helper cells. They are found at the interfaces between the external environment and the internal environment, e.g., skin and lining of the GI tract.
  • the colostrum-derived immunoglobulin preparations of the invention may promote regulatory T cells or any other cell related to the immune system in an antigen specific and non specific manner, by targeting bystander antigens, or by being directed towards non associated antigens.
  • the immunoglobulin preparation of the invention may be antigen or disease specific or alternatively, may augment or induce specific cells or parts of the immune system in a non-antigen specific way, including an immune bystander effect. It should be further appreciated that the immunoglobulin preparation of the invention may be used either for an active or a passive treatment.
  • the . colostrum-derived immunoglobulin preparation may comprise monomeric, dimeric or multimeric immunoglobulin selected from the group consisting of IgG, IgA and IgM and any fragments thereof.
  • the principal compositional difference between colostrum and mature milk is the very high content of colostral immunoglobulin, of which IgG class makes up 80-90%, as demonstrated by Table 1.
  • the colostrum-derived immunoglobulin preparation mainly comprises IgG, specifically, IgGl and IgG2.
  • Immunoglobulin G is a multimeric immunoglobulin, built of two heavy chains ⁇ and two light chains. Each complex has two antigen binding sites. This is the most abundant immunoglobulin and is approximately equally distributed in blood and in tissue liquids, constituting 75% of serum immunoglobulins in humans. In general, the number of IgG subclasses varied widely between different species, ranging from one subclass in rabbits to seven subclasses in horses, making it difficult to find orthologues. In humans, for example, IgGl and IgG3 are the most pro-inflammatory IgG subclasses. In mice, however, IgG2a and IgG2b are the most pro-inflammatory IgG molecules showing a greater activity than mouse IgGl and IgG3 in many in vivo model systems.
  • FcRs Fc receptors
  • IgG IgG
  • Fc ⁇ Rs Fc receptors
  • IgG systemic lupus erythematosus
  • the preparation of the immuno-modulatory composition of the invention may activate an Fc ⁇ Rs-mediated signaling pathway (either by the activating Fc ⁇ Rs or the inhibitory Fc ⁇ Rs).
  • the immunoglobulin preparation may comprises a secretory antibody, specifically, slgA.
  • IgA and IgM are secreted by a number of exocrine tissues.
  • IgA is the predominant secretory immunoglobulin present in colostrum, saliva, . tears, bronchial secretions, nasal mucosa, prostatic fluid, vaginal secretions, and mucous secretions from the small intestine.
  • IgA output exceeds that of all other immunoglobulins, making it the major antibody produced by the body daily and is the major immunoglobulin found in human milk, whey and colostrum.
  • IgM secretion is less abundant but can increase to compensate for deficiencies in IgA secretion.
  • IgA J chain containing IgA is produced and secreted by plasma B immunocytes located in the lamina basement membrane just beneath, the basement membrane of exocrine cells.
  • IgA has a typical immunoglobulin four-chain structure (M r 160,000) made up of two heavy chains (M r 55,000) and two light chains (M r 23,000).
  • M r 160,000 immunoglobulin four-chain structure
  • IgAl and IgA2 that have 1 and 2 heavy chains, respectively.
  • IgA can occur as monomers, dimers, trimers or multimers. In plasma, 10% of the total IgA is polymeric while the remaining 90% is monomeric.
  • the secreted IgA binds to a M r 100,000 poly-Ig receptor positioned in the basolateral surface of most mucosal cells.
  • the receptor-IgA complex is next translocated to the apical surface where IgA is secreted.
  • the binding of dimeric IgA to the poly-Ig receptor is completely dependent upon the presence of a J chain. Monomeric IgA will not bind to the receptor.
  • IgG The difference in function of IgG and IgA, follows the position where the molecules operate. IgA is found mainly on mucosal surfaces where there is little in the way of tissue fluid to carry immune cells and chemicals. Therefore, IgA (often as a dimer) would be preferably used for physical neutralisation of pathogens, and may be too effective at other immune functions. IgGs are present in the tissue fluid and blood where there is the full collection of leukocytes, complement system, macrophages etc.
  • phagocytes e.g.' Killer T cells and macrophages
  • the immunoglobulin preparations may be obtained from any one of colostrum, colostrum serum, hyperimmunised milk or colostrum, colostrum whey (either cheese or casein), cheese or casein whey, directly from skim milk, whole milk, or a reconstituted form of such streams.
  • the immunoglobulin, preparation comprised within the composition of the invention may be any fraction of colostrum.
  • colostrum where used herein includes colostral milk, processed colostral-milk such as colostral milk processed to partly or completely removes one or more of fat, cellular debris, lactose and casein.
  • the colostrum, or milk, containing antigen-specific antibodies is preferably collected by milking the animal colostrum or milk thus collected can either be used directly, may be further processed, for instance to purify antigen- specific antibodies.
  • Methods for the (partial) purification of (antigen-specific) antibodies from colostrum or milk are present in the art and the following Example 1.
  • any adjuvants may be added to the compositions of the invention.
  • Appropriate adjuvants therefore may be any antigen, antibody, glycosphingolipids, proteins, cytokines, adhesion molecules, and component that can activate or alter the function of antigen presenting cell or of any other cell related to the immune system in a direct and indirect manner.
  • the immunoglobulin preparation may be an affinity purified antibody or any fragment thereof.
  • antibody is meant to include both intact molecules as well as fragments thereof, such as, for example, Fab and F(ab')2, which are capable of binding antigen.
  • Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody.
  • Fab and F(ab')2 and other fragments of the antibodies useful in the present invention may be used for immuno -modulation, according to the methods disclosed herein for intact antibody molecules.
  • Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments).
  • An antibody is said to be "capable of specifically recognizing" a certain antigen if it is capable of specifically reacting with an. antigen which is in this particular example an antigen or a mixture of antigens specific for a certain immune-related disorder, to thereby bind the molecule to the antibody.
  • an "antigen” is a molecule or a portion of a molecule capable of being bound by an antibody, which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen.
  • An antigen may have one or more than one epitope.
  • epitope is meant to refer to that portion of any molecule capable of being bound by an antibody that can also be recognized by that antibody.
  • Epitopes or "antigenic determinants” usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains, and have specific three-dimensional structural characteristics as well as specific charge . characteristics .
  • the immunoglobulin preparation used as an active ingredient for the composition of the invention may be obtained from a mammal immunized with at least one antigen or a mixture of at least two antigens specific for said disorder.
  • the antigen used for immunizing said mammal preferably, bovine
  • the antigen used for immunizing said mammal may be provided as any one of an isolated and purified peptide, a purified recombinant protein, a fusion protein, cell lysate, membranal preparation, nuclear preparation, or cytosolic preparation of any one of tissue culture cells, primary cells or tissue samples obtained from a subject suffering from said disorder.
  • the composition of the invention may optionally further comprise colostrum component/s such as for example, alarmins, defenensins, colostrinin, and any other colostrum or milk derived carbohydrates, glycolipids or any other molecules or components that may further enhance or inhibit modulation of an immune response, or any preparations, mixtures or combinations thereof.
  • the composition of the invention may comprise any additional adjuvant.
  • Appropriate adjuvants therefore may be any antigen, antibody, glycosphingolipids, proteins, cytokines, adhesion molecules, and component that can activate or alter the function of antigen presenting cell or of any other cell related to the immune system in a direct and indirect manner.
  • the present invention further provides the use of colostrum or any colostrum-derived preparations for enhancing an immunomodulatory effect of an immunomodulatory therapeutic agent.
  • Such colostrum-derived preparations may be therefore combined with any immunomodulatory therapeutic agent/s or any combination or mixture thereof, creating a combined immunomodulatory composition for the treatment and/or prevention of immune-related disorders, specifically, Metabolic Syndrome, autoimmune disorders, malignant and non- malignant proliferative disorder, genetic disease, infectious diseases and neurodegenerative disorders.
  • the composition of the invention is intended for preventing and/or treating an immune-related disorder
  • disorder refers to a condition in which there is a disturbance of normal functioning.
  • a “disease” is any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.
  • the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function, while in other contexts these may be considered distinguishable categories. It should be noted that the terms “disease”, “disorder”, “condition” and “illness”, are equally used herein.
  • an "immune-related disorder or disease” may be any disorder associated with, caused by, linked to, a non normal immune response. Such disorders may usually occur together with a disturbed immune response, or believed to have an impact on or by a non normal immune response.
  • the immunoglobulin preparations comprised within the composition of the invention recognize and bind at least one antigen specific for a disorder to be treated. Such recognition leads to alteration of regulatory T cells, and as a result, causes modulation of the Thl/Th2, Trl/Th3 cell balance either toward an anti-inflammatory Th2, Trl/Th3 immune response or toward a pro-inflammatory ThI immune response. Thereby inhibiting or activating an immune response specifically directed toward said disorder.
  • any type of regulatory or effector cells specifically regulatory T cells, including Th3 and TrI [TH3, T cells are preferentially induced at mucosal surfaces and secrete transforming growth factor (TGF)-B] cells may be involved.
  • TGF transforming growth factor
  • the colostrum-derived immunoglobulin preparations of the invention may promote regulatory T cells or any other cell related to the immune system in an antigen specific and non specific way, by targeting bystander antigens, or by being directed against non associated antigens.
  • the immunoglobulin preparation recognizes and binds at least one antigen specific for said disorder and modulates immune-regulatory cells, specifically, regulatory T cells. Such modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance toward an anti-inflammatory Th2, Trl/Th3 immune response thereby inhibiting an immune response specifically directed toward said disorder.
  • the immunoglobulin preparation of the invention may be directed to antigens that are not specific to the treated disorder.
  • antigens may be any target immune-related components having a modulatory effect on the immune-response.
  • recognition of such disease non-specific antigens by the immunoglobulin preparation of the invention may results in alteration of the immune-response.
  • Such modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance toward an anti-inflammatory Th2, Trl/Th3 immune response thereby inhibiting an immune response specifically directed toward said disorder.
  • the immunomodulatory composition of the invention may lead to a Th2, Trl/Th3 anti-inflammatory response. More specifically, such anti-inflammatory response may be accompanied by a decrease or reduction in the amount or expression of pro-inflammatory cytokines such as IL-2, IL-17, IL-23, IFN- ⁇ , IL-6.
  • Such decrease or reduction according to the invention may be a reduction of about 5% to 99%, specifically, a reduction of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% as compared to untreated control.
  • the composition of the invention may elevate and increase the amount or expression of anti-inflammatory cytokines such as TGFr ⁇ , IL-10, IL-4, IL-5, IL-9 and IL-13. More specifically, the increase, induction or elevation of the anti-inflammatory cytokines may be an increase of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% as compared to untreated control.
  • anti-inflammatory cytokines such as TGFr ⁇ , IL-10, IL-4, IL-5, IL-9 and IL-13. More specifically, the increase, induction or elevation of the anti-inflammatory cytokines may be an increase of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% as compared to untreated control.
  • such Th2, Trl/Th3 response directing composition may be used for treating immune related disorder such as Metabolic Syndrom, graft rejection pathology, inflammatory disease and an autoimmune disease.
  • the anti-inflammatory effect of the immunomodulatory composition of the invention may be achieved by activation or promotion of specific subsets of regulatory cells, antigen presenting cells or any type of cell-cell contact, or via direct or indirect activation of cytokines and/or chemokins. It should be further noted that any type of regulatory or effector cell, specifically regulatory T cells, including Th3 and TrI cells may be involved.
  • the colostrum-derived immunoglobulin preparations of the invention may promote regulatory T cells or any other cell related to the immune system in an antigen specific and non specific way, by targeting bystander antigens, or by being directed against non associated antigens.
  • an immune-related cell activated or promoted by the composition of the invention may be an APC (such as DC), Treg cell or any other cell associated directly on indirectly with the immune system including but not limited to platelets, macrophages, any type of B cell, T cell (including double negative cells), and any type of non-professional antigen presenting cell, adipocytes, endothelial cell, any type of cell that is part of an organ, specifically, an organ connected to the treated immune- related disorder and any type of cell having regulatory enhancing or suppressing properties.
  • the composition of the invention demonstrate immuno-modulation, specifically, either antiinflammatory or pro-inflammatory effect on immune-related cells such as specific T regulatory cells for example, adipocytes and Antigen Presenting Cells (APC), such as DC.
  • APC Antigen Presenting Cells
  • the composition of the invention may be used for inducing at least one of T regulatory (Treg) cells, or any cell having regulatory properties, either suppressive or inductive, adipocyte and Antigen Presenting Cells (APC) in a subject suffering from an immune-related disorder.
  • T regulatory T regulatory
  • APC Antigen Presenting Cells
  • an antigen specific for an immune-related disorder may be insulin.
  • the colostrum- derived immunoglobulin preparation comprises anti-insulin antibodies. More particularly, as shown by the following Examples, the colostrum- derived anti-insulin antibodies of the invention clearly promote regulatory T cells accumulation, specifically, of CD4 + CD25 + Foxp3 + , CD4 + CD25 + Foxp3 + IL17+ and CD8 + CD25 T regulatory cells in adipose tissue and in adipose tissue associated stromal vascular cells in a subject suffering of a Metabolic Syndrome or any of the conditions comprising the same.
  • Adipocytes are the cells that primarily compose adipose tissue, specialized in storing energy as fat.
  • adipose tissue white adipose tissue (WAT) and brown adipose tissue (BAT), which are also known as white fat and brown fat, respectively, and comprise the two types of fat cells.
  • WAT white adipose tissue
  • BAT brown adipose tissue
  • White fat cells or monovacuolar cells contain a large lipid droplet surrounded by a layer of cytoplasm. The nucleus is flattened and located on the periphery.
  • a typical fat cell is 0.1mm in diameter with some being twice that size and others half that size.
  • the fat stored is in a semi- liquid state, and is composed primarily of triglycerides and cholesteryl ester.
  • White fat cells secrete resistin, adiponectin, and leptin. Brown fat cells or pluri vacuolar cells are polygonal in shape. Unlike white fat cells, these cells have considerable cytoplasm, with lipid droplets scattered throughout. The nucleus is round, and, although eccentrically located, it is not in the periphery of the cell. The brown color comes from the large quantity of mitochondria. As shown, by the Examples, the composition of the invention, significantly decreased the serum levels of triglycerides, ALT 5 AST and Glucose. Example 2 further shows that the composition of the invention leads to a significant increase in sensitivity to insulin.
  • the pharmaceutical composition of the invention leads to at least one of a decrease in the serum levels of cholesterol, triglycerides, ALT, AST and Glucose and an increase in the sensitivity to insulin or decrease in insulin resistance in a subject suffering of an immune -related disorder, for example, Metabolic syndrome.
  • an immune -related disorder for example, Metabolic syndrome.
  • the composition of the invention leads to a reduction of about 5% to 99% of the serum level of any one of triglycerides, ALT, AST and Glucose, in a subject suffering of an-immune- related disorder.
  • such reduction may be a reduction of about, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% and over 99%, as compared to the levels prior to the treatment, or the levels of untreated control.
  • increase, elevation, enhancement, induction it is meant that the composition of the invention leads to induction, or increase of about 5% to 99% of the sensitivity to insulin in a subject suffering of an-immune- related disorder, such as metabolic syndrome. More specifically, such increase may be an.
  • the composition of the invention may further lead to a significant reduction in hepatic fat accumulation. Such reduction may be of about 5%-99% as compared to untreated control, as indicated above.
  • the composition of the invention may be used for preventing and/or treating autoimmune disease for example, Metabolic Syndrome or any of the conditions comprising the same, any condition associated with, caused by, linked to or believed to have an impact on metabolic syndrome, for example, at least one of dyslipoproteinemia (hypertriglyceridemia, hypercholesterolemia, low HDL-cholesterol), obesity, NIDDM (non-insulin dependent diabetes mellitus), IGT (impaired glucose tolerance), blood coagulability, blood fibrinolysis defects and hypertension.
  • dyslipoproteinemia hyperlipoproteinemia
  • hypercholesterolemia hypercholesterolemia
  • low HDL-cholesterol low HDL-cholesterol
  • obesity non-insulin dependent diabetes mellitus
  • IGT impaired glucose tolerance
  • blood coagulability blood fibrinolysis defects and hypertension.
  • Atherogenic dyslipidemia blood fat disorders — high triglycerides, low HDL cholesterol and high LDL cholesterol - that foster plaque buildups in artery walls); *Elevated blood pressure; *Insulin resistance or glucose intolerance; *Pro thrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor— 1 in the blood); and *Proinflammatory state (e.g., elevated C-reactive protein in the blood).
  • People with the metabolic syndrome are at increased risk of coronary heart disease and other diseases related to plaque buildups in artery walls (e.g., stroke and peripheral vascular disease) and type 2 diabetes.
  • composition of the invention is intended for the treatment of dyslipoproteinemia, which may include hypertriglyceridemia, hypercholesterolemia and low HDL-cholesterol, obesity, NIDDM (non- insulin dependent diabetes mellitus type 2), IGT (impaired glucose tolerance), blood coagulability, blood fibronolysis defects and hypertension.
  • dyslipoproteinemia may include hypertriglyceridemia, hypercholesterolemia and low HDL-cholesterol, obesity, NIDDM (non- insulin dependent diabetes mellitus type 2), IGT (impaired glucose tolerance), blood coagulability, blood fibronolysis defects and hypertension.
  • the immunomodulatory composition of the invention may be used for treating diabetes, particularly, Type 2 diabetes.
  • Diabetes mellitus often simply diabetes, is a syndrome characterized by disordered metabolism and inappropriately high, blood sugar (hyperglycaemia) resulting from either low levels of the hormone insulin or from abnormal resistance to insulin's effects coupled with inadequate levels of insulin secretion to compensate.
  • the characteristic symptoms are excessive urine production (polyuria), excessive thirst and increased fluid intake (polydipsia), and blurred vision. These symptoms are likely absent if the blood sugar is only mildly elevated.
  • Type 1 diabetes is usually due to autoimmune destruction of the pancreatic beta cells.
  • Type 2 diabetes is characterized by insulin resistance ih target tissues, this causes a need for abnormally high amounts of insulin and diabetes develops when the beta cells cannot meet this demand.
  • Gestational diabetes is similar to type 2 diabetes in that it involves insulin resistance, hormones in pregnancy may cause insulin resistance in women genetically predisposed to developing this condition.
  • Acute complication of diabetes may occur if the disease is not adequately controlled.
  • Serious long-term complications include cardiovascular disease (doubled risk), chronic renal failure, retinal damage (which can lead to blindness), nerve damage (of several kinds), and microvascular damage, which may cause impotence and poor healing. Poor healing of wounds, particularly of the feet, can lead to gangrene, which may require amputation.
  • the immunomodulatory composition of the invention may be used for the treatment of Type 1 diabetes.
  • Type 1 diabetes mellitus is characterized by loss of the insulin-producing beta cells of the islets of Langerhans in the pancreas, leading to a deficiency of insulin. The main cause of this beta cell loss is. a T-cell mediated autoimmune attack.
  • the pharmaceutical composition of the invention may be used for the treatment of an autoimmune disorder.
  • autoimmune disorders include, but are not limited to, Alopecia Areata, Lupus, Ankylosing Spondylitis, Meniere's Disease, Antiphospholipid Syndrome, Mixed Connective Tissue Disease, Autoimmune Addison's Disease, Multiple Sclerosis, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Autoimmune Hepatitis, Pemphigus Vulgaris, Behcet's Disease, Pernicious Anemia, Bullous Pemphigoid, Polyarthritis Nodosa, Cardiomyopathy, Polychondritis, Celiac Sprue-Dermatitis, Polyglandular Syndromes, Chronic Fatigue Syndrome (CFIDS), Polymyalgia Kheumatica, Chronic Inflammatory Demyelinating, Polymyositis and Dermatomyositis, Chronic Inflammatory Polyneuropathy, Primary Agammaglobulinemia, Chur
  • compositions described herein can be administered to a subject to treat or prevent disorders associated with an abnormal or unwanted immune response associated with cell, tissue or organ transplantation, e.g., renal, hepatic, and cardiac transplantation, e.g., graft versus host disease (GVHD), or to prevent allograft rejection.
  • disorders associated with an abnormal or unwanted immune response associated with cell, tissue or organ transplantation e.g., renal, hepatic, and cardiac transplantation, e.g., graft versus host disease (GVHD), or to prevent allograft rejection.
  • GVHD graft versus host disease
  • an autoimmune disease treated by the composition of the invention may be any one of rheumatoid arthritis, type 1 diabetes, type 2 diabetes, artherosclerosis, asthma, acute and chronic graft versus host disease, systemic lupus erythmatosus, scleroderma, multiple sclerosis, inflammatory bowel disease, psoriasis, uvietis, thyroiditis and immune mediated hepatitis.
  • the composition of the invention may be used for the treatment of MS.
  • MS Multiple Sclerosis
  • MS is typically characterized clinically by recurrent or chronically progressive necrologic dysfunction, caused by lesions in the CNS.
  • the lesions include multiple areas of demyelination affecting the brain, optic nerves, and spinal cord.
  • the underlying etiology is uncertain, but MS is widely believed to be at least partly an autoimmune or immune-mediated disease.
  • the invention includes compositions and methods of treating, delaying or preventing the onset of MS, by orally or mucosally administering the colostrum- derived immunoglobulin preparation of the invention. Included are methods wherein a subject who has or is at risk of having MS is orally administered with the composition of the invention.
  • the composition of the invention may be used for the treatment of RA.
  • Rheumatoid arthritis is the most common chronic inflammatory arthritis and affects about 1% of adults, it is two to three times more prevalent in women than in men. RA may begin as early as infancy, but onset typically occurs in the fifth or sixth decade.
  • Diagnosis may be made according to the American Rheumatism Association Criteria for the so Classification of Rheumatoid Arthritis.
  • a therapeutically effective amount will cause an improvement in one or more of the following: the number of inflamed joints, the extent of swelling, and the range of joint motion.
  • Laboratory measurements e.g., ESR and hematocrit value
  • assessments of subjective features e.g., pain and morning stiffness
  • the invention also includes methods of treating autoimmune arthritis, e.g., RA, in a subject by administering to the subject a therapeutically effective amount of composition of the invention comprising colostrum-derived immunoglobulin preparations.
  • compositions of the invention described herein can also be used to treat or prevent graft rejection in a transplant recipient.
  • the compositions can be used in a wide variety of tissue and organ transplant procedures, e.g., the compositions can be used to induce central tolerance in a recipient of a graft of cells, e. g., stem cells such as bone marrow and/or of a tissue or organ such as pancreatic islets, liver, kidney, heart, lung, skin, muscle, neuronal tissue, stomach, and intestines.
  • the new methods can be applied in treatments of diseases or conditions that entail cell, tissue or organ transplantation (e.g., liver transplantation to treat hypercholesterolemia, transplantation of muscle cells to treat muscular dystrophy, or transplantation of neuronal tissue to treat Huntington's disease or Parkinson's disease).
  • diseases or conditions that entail cell, tissue or organ transplantation (e.g., liver transplantation to treat hypercholesterolemia, transplantation of muscle cells to treat muscular dystrophy, or transplantation of neuronal tissue to treat Huntington's disease or Parkinson's disease).
  • the composition of the invention may modulate the Thl/Th2, Th3 balance towards an anti-Th2, Trl/Th3 response in a subject suffering from IBD. Therefore, according to this embodiment, the composition of the invention is intended for treating IBD.
  • IBD Inflammatory bowel diseases
  • T cell-mediated immunity including coetaneous anergy and diminished responsiveness to T cell stimuli, have also been described in these patients.
  • changes in mucosal cell mediated immunity were identified, including increased concentrations of mucosal IgG cells and changes in T cells subsets, suggesting antigen stimulation.
  • the composition of the invention may be used for the treatment of atherosclerosis.
  • Atherosclerosis is a slowly progressive disease characterized by the accumulation of cholesterol within the arterial wall.
  • the atherosclerotic process begins when LDL-C becomes trapped within the vascular wall. Oxidation of the LDL-C results in the bonding of monocytes to the endothelial cells lining the vessel wall. These monocytes are activated and migrate into the endothelial space where they are transformed into macrophages, leading to further oxidation of LDL-C.
  • the oxidized LDL-C is taken up through the scavenger receptor on the macrophage leading the formation of foam cells.
  • a fibrous cap is generated through the proliferation and migration of arterial smooth muscle cells, thus creating an atherosclerotic plaque.
  • Lipids depositing in atherosclerotic legions are derived primarily from plasma apo B containing lipoproteins. These include chylomicrons, LDL-C, IDL, and VLDL. This accumulation forms bulky plaques that inhibit the flow of blood until a clot eventually forms, obstructing an artery and causing a heart attack or stroke.
  • the immunoglobulin preparation used by the composition of the invention may recognize and bind at least one antigen specific for the treated disorder and may modulates immune-regulatory cells, specifically, regulatory T cells. Such modulation may results for example, in modulation of the Thl/Th2 cell balance toward a pro-inflammatory ThI immune response thereby activating an immune response specifically directed toward said disorder.
  • the pro -inflammatory effect of the immunomodulatory composition of the invention may be achieved by activation or promotion of specific subsets of regulatory cells, antigen presenting cells or any type of cell-cell contact via direct or indirect activation, of cytokines, and/or chemokines.
  • modulation of the Thl/Th2, Th3 balance towards a pro-inflammatory ThI response may be particularly applicable in immune related disorders having an undesired unbalanced anti-inflammatory Th2, Trl/Th3 response, for example, a malignant and non-malignant proliferative disorder, infectious disease, genetic disease and neurodegenerative disorders.
  • the composition of the invention may be used for the prevention and/or treatment of a malignant proliferative disorder that may be a solid or non-solid tumor, for example, carcinoma, sarcoma, melanoma, leukemia, myeloma or lymphoma.
  • a malignant proliferative disorder that may be a solid or non-solid tumor, for example, carcinoma, sarcoma, melanoma, leukemia, myeloma or lymphoma.
  • the composition of the invention is intended for preventing and/or treating carcinoma such as hepaotcellular carcinoma, prostate cancer, breast carcinoma, colon carcinoma.
  • the composition of the invention may be used for preventing and/or treating leukemia, more specifically, acute or chronic leukemia.
  • cancer As used herein to describe the present invention, "cancer”, “tumor” and “malignancy” all relate equivalently to a hyperplasia of a tissue or organ. If the tissue is a part of the lymphatic or immune systems, malignant cells may include non-solid tumors of circulating cells. Malignancies of other tissues or organs may produce solid tumors. In general, the methods and compositions of the present invention may be used in the treatment of non-solid and solid tumors.
  • Malignancy as contemplated in the present invention may be selected from the group consisting of carcinomas, melanomas, lymphomas and sarcomas.
  • Malignancies that may find utility in the present invention can comprise but are not limited to hematological malignancies (including leukemia, lymphoma and myeloproliferative disorders), hypoplastic and aplastic anemia (both virally induced and idiopathic), myelodysplastic syndromes, all types of paraneoplastic syndromes (both immune mediated and idiopathic) and solid tumors (including lung, liver, breast, colon, prostate GI tract, pancreas and Karposi). More particularly, the malignant disorder may be hepaotcellular carcinoma, colon cancer, melanoma, myeloma and acute or chronic leukemia.
  • the composition of the invention is intended for the prevention and/or treatment of neurodegenerative disorders.
  • neurodegenerative diseases include: Alzheimer's disease, Parkinson's disease, ALS (Amyotrophic Lateral Sclerosis), Huntington's disease, taupathies such as Pick's disease, fronto temporal dementia, cortico-basal degeneration and progressive supranuclear palsy and Spongiform encephalopathies such as Scrapie, mad cow disease and Bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, Fatal Familial Insomnia, Gerstmann-Straussler-Scheinker syndrome and Kuru.
  • the immuno- activating composition of the invention may be further applicable for preventing and/or treating infectious diseases caused by bacterial infections, viral infections, fungal infections, or parasitic infections.
  • More specific embodiment relates to the use of the colostrums-derived immunoglobulin preparation of the invention for treating infectious diseases cased by Clostridium difficile.
  • Clostridium difficile-associated diarrhea as used herein is one of the most common nosocomial infections in the United States, with reported incidence rates of between l%-20% of hospitalized patients.
  • a continuum of disease from mild diarrhea to antibiotic-associated colitis (AAC) to pseudomembranous colitis (PMC), toxic megacolon, colonic perforation and death are caused by C. difficile, an anaerobic, spore- forming bacillus.
  • Nosocomial infections are of serious concern not only for the morbidity and mortality they cause but for the financial burden they place on health care systems.
  • the mammalian subject used for obtaining a colostrum-derived immunoglobulin preparation are farm animals.
  • Means and methods of the invention are suited to obtain high and prolonged antigen-specific antibody production in the colostrum, milk or milk products of any lactating mammal.
  • said animal is a farm- animal.
  • Farm animals are animals that are used on a commercial basis by man, be it for the production of milk, meat or even antibodies. Farm- animals already used for the commercial scale production of milk are preferred for the present invention since for these animals special lines and/or breeds exist that are optimized for milk production.
  • said farm-animal is a cow or a goat. More preferably said farm-animal is a cow.
  • any of the . compositions of the invention may be administered orally or by inhalation as an aerosol or by intravenous, intramuscular, subcutaneous, intraperitoneal, perenteral, transdermal, intravaginal, intranasal, mucosal, sublingual, topical, rectal or subcutaneous administration, or any combination thereof.
  • composition of the invention may be suitable for mucosal administration, for example, pulmonary, buccal, nasal, intranasal, sublingual, rectal, vaginal administration and any combination thereof.
  • Althogh oral and nasal administration are preferred, it should be appreciated that any other route of administration may be applicable, for example, intravenous, intravenous, intramuscular, subcutaneous, intraperitoneal, parenteral, intravaginal, intranasal, mucosal, sublingual, topical,rectal or subcutaneous administration, or any combination thereof.
  • the immunoglobulin preparation used by the compositions of the invention may be prepared in preparations such as food additives, aqueous solutions, oily preparations, emulsions, gels, etc., and these preparations may be administered orally, topically, rectally, nasally, bucally, or vaginally.
  • the preparations may be administered in dosage formulations containing conventional non-toxic acceptable carriers and may also include one or more acceptable additives, including acceptable salts, polymers, solvents, buffers, excipients, bulking agents, diluents, excipients, suspending agents, lubricating agents, adjuvants, vehicles, delivery systems, emulsifiers, dis-integrants, absorbents, preservatives, surfactants, colorants, flavorants or sweeteners.
  • An optional dosage form of the present invention may be a powder for incorporation into beverages, pills, syrup, capsules, tablets, granules, beads, chewable lozenges or food additives, using techniques known in the art.
  • immuno- modulating composition of the invention may be administered in a form selected from the group consisting of orally-active powders, pills, capsules, teas, extracts, dried extracts, subliguals, sprays, dispersions, solutions, suspensions, emulsions, foams, syrups ,lotions, ointments, gels, pastes, dermal pathces, injectables, vaginal creams and suppositories.
  • Therapeutic formulations may be administered in any conventional dosage formulation.
  • Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof.
  • Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient.
  • Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal or by inhalation) administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The nature, availability and sources, and the administration of all such compounds including the effective amounts necessary to produce desirable effects in a subject are well known in the art and need not be further described herein.
  • compositions are well known in the art and has been described in many articles and textbooks, see e.g., Remington's Pharmaceutical Sciences, Gennaro A. R. ed., Mack Publishing Co., Easton, PA, 1990, and especially pp. 1521-1712 therein, fully incorporated herein by reference.
  • composition of the invention can be administered and dosed in accordance with good medical practice.
  • composition of the invention may comprise the active substance in free form and be administered directly to the subject to be treated.
  • Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof.
  • Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient.
  • Formulations include those suitable for oral, nasal, or parenteral (including subcutaneous (s.c), intramuscular (i.m.), intraperitoneal (i.p.), intravenous (i.v.) and intradermal or by inhalation to the lung mucosa) administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The nature, availability and sources, and the administration of all such compounds including the effective amounts necessary to produce desirable effects in a subject are well known in the art and need not be further described herein.
  • compositions of the invention generally comprise a buffering agent, an agent that adjusts the osmolarity thereof, and optionally, one or more pharmaceutically acceptable carriers, excipients and/or additives as known in the art.
  • Supplementary active ingredients can also be incorporated into the compositions.
  • the carrier can be solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic composition is contemplated.
  • the active drug components can be combined with a non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, modified sugars, modified starches, methylcellulose and its derivatives, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, and other reducing and non-reducing sugars, magnesium stearate, stearic acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate and the like.
  • a non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, modified sugars, modified starches, methylcellulose and its derivatives, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, and other reducing and non-reducing sugars, magnesium stearate, stearic acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate and the like.
  • the active drug components can be combined with non-toxic pharmaceutically acceptable inert carriers such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrating agents and coloring and flavoring agents can also be incorporated into the mixture.
  • Stabilizing agents such as antioxidants, propyl gallate, sodium ascorbate, citric acid, calcium metabisulphite, hydroquinone, and 7-hydroxycoumarin can also be added to stabilize the dosage forms.
  • Other suitable compounds can include gelatin, sweeteners, natural and synthetic gums such as acacia, tragacanth, or alginates, carboxymethylcellulose, polyethylene, glycol, waxes and the like.
  • the invention relates to the use of mammalian colostrum-derived, milk or milk-products-derived immunoglobulin preparation for preparing an immuno-modulating composition for the treatment and prophylaxis of an immune-related disorder.
  • the immunoglobulin preparation used by the invention recognizes and binds at least one antigen specific for said disorder and modulates immune -regulatory cells, specifically, regulatory T cells. Such modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance thereby activating or inhibiting an immune response specifically directed toward said disorder.
  • the immunoglobulin preparation used by the invention may be directed to antigens that are not specific to the treated disorder.
  • Such antigens may be any target immune -related components having a modulatory effect on the immune-response. Thereby, recognition of such disease non-specific antigens by the immunoglobulin preparation of the invention may results in alteration of the immune -response.
  • the immuno-modulatory effect of the composition of the invention may be achieved by activation or promotion of specific subsets of regulatory cells, antigen presenting cells, or any type of cell-cell contact via direct or indirect activation of cytokine/s and/or chemokines.
  • composition of the invention may involve active use of the antibodies.
  • active use of the antibodies for example, by activation of specific regulatory T cells, B cells, antigen presenting cells, or any type of effector or regulatory cells that is associated with an effect on the immune system, or inducing the secretion of cytokines or chemokines or affecting the immune system in any other way.
  • the immunoglobulin preparation used by the invention may be antigen or disease specific or alternatively, may target a disease non-specific component of the immune-system and thereby may augment or induce specific cells or parts of the immune system in a non antigen specific way, including an immune bystander effect, or non disease target antigens.
  • the invention further optionally uses further colostrum, milk or milk products component/s and any adjuvant/s, for the preparation of such composition.
  • the colostrum-derived, milk or milk products-derived immunoglobulin preparation used by the invention comprises monomeric, dimeric and multimeric immunoglobulin selected from the group consisting of IgG, IgA and IgM and any fragments thereof.
  • the immunoglobulin preparation used by the invention mainly comprises IgG, specifically, IgGl and/or IgG2.
  • the immunoglobulin preparation used by the invention may comprise dimeric secretory IgA or any fragment thereof.
  • the use according to the invention of colostrum-derived, milk or milk products-derived immunoglobulin preparation is for preparing a composition that optionally may further comprises colostrum, milk or milk products component/s and any adjuvant/s, preferably, alarmins, defenensins, colostrinin and any preparation, mixture or combination thereof.
  • the composition of the invention may comprise any additional adjuvant.
  • Appropriate adjuvants therefore may be any antigen, antibody, glycosphingolipids, proteins, cytokines, adhesion molecules, and component that can activate or alter the function of antigen presenting cell or of any other cell related to the immune system in a direct and indirect manner.
  • the present invention further provides the use of colostrum or any colostrum-derived preparations for enhancing an immunomodulatory effect of an immunomodulatory therapeutic agent.
  • alarmin denotes an array of structurally diverse multifunctional host proteins that are rapidly released during infection or tissue damage, and that have mobilizing and activating effects on receptor-expressing cells engaged in host defence and tissue repair.
  • Innate-immune mediators that have alarmin function include defensins, eosinophil-derived neurotoxin, cathelicidins and HMGBl.
  • Defensins are small (15-20 residue) cysteine-rich cationic proteins found in both vertebrates and invertebrates. They are active against bacteria, fungi and enveloped viruses. They consist of 15-20 amino acids including six to eight conserved cysteine residues. Cells of the immune system, contain these peptides to assist in killing phagocytized bacteria, for example in neutrophil granulocytes and almost all epithelial cells. Most defensins function by penetrating the microbial's cell membrane by way of electrical attraction, and once embedded, forming a pore in the membrane which allows efflux.
  • Colostrinin refers to a polypeptide which, in its natural form, is obtained from mammalian colostrum. Colostrinin is sometimes known as “colostrinine", and has a molecular weight in the range 16,000 to 26,000 Daltons. Colostrinin may form a dimer or trimer of sub-units (each having a molecular weight in the range 5,000 to 10,000 Daltons, preferably 6,000 Daltons), and contains mostly praline (the amount of proline is greater than the amount of any other single amino acid).
  • Colostrinin is characterized in that it stimulates the production of cytokines, especially gamma interferon (IFN- ⁇ ), tumor necrosis factor (TNF- ⁇ ), iiiterleukins (e.g. IL-6 and IL-10) and various growth factors.
  • IFN- ⁇ gamma interferon
  • TNF- ⁇ tumor necrosis factor
  • iiiterleukins e.g. IL-6 and IL-10
  • the imm ⁇ noglobulin preparation used by the invention may be obtained from a mammal, ' preferably a cow, immunized with at least one antigen or a mixture of at least two antigens specific for the disorder to be treated.
  • the invention thus provides the use of a colostrum-derived immuno- preparation for the preparation of an immuno-modulatory composition for the treatment and/or prevention of immune-related disorders.
  • the immunoglobulin preparation used by the invention recognizes and binds at least one antigen specific for a disorder to be treated.
  • the immunoglobulin preparation of the invention may be directed to antigens that are not specific to the treated disorder.
  • antigens may be any target immune-related components having a modulatory effect on the immune-response.
  • the immunoglobulin of the invention modulates immune-regulatory cells, specifically, regulatory T cells. Such modulation may results for example, in modulation of the Thl/Th2, Trl/Th.3 cell balance toward either an antiinflammatory Th2, Trl/Th3 immune response or toward a proinflammatory ThI immune response thereby inhibiting or activating an immune response specifically directed toward the disorder to be treated.
  • the immunoglobulin preparation used by the invention recognizes and binds at least one antigen specific for the disorder to be treated and modulates immune-regulatory cells, specifically, regulatory T cells.
  • the immunoglobulin preparation of the invention may be directed to antigens that are not specific to the treated disorder.
  • antigens may be any target immune-related components having a modulatory effect on the immune-response. Such modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance toward an antiinflammatory Th2, Trl/Th3 immune response thereby inhibiting an immune response specifically directed toward said disorder.
  • an immune related disorder prevented and/or treated by such composition may be any one of Metabolic Syndrome or any of the conditions comprising the same, graft rejection pathology, inflammatory disease, an autoimmune disease and a non alcoholic fatty liver disease, hyperlipidemia and atherosclerosis.
  • an antigen specific for an immune-related disorder used by the invention may be insulin.
  • the colostrum-derived immunoglobulin preparation comprises anti-insulin antibodies.
  • the anti insulin immunoglobulin preparations of the invention clearly promote regulatory T cells accumulation in adipose tissue and in adipose tissue associated stromal vascular cells, in a subject suffering of a Metabolic Syndrome or any of the conditions comprising the same.
  • the colostrum-derived anti-insulin antibodies of the invention lead to accumulation of CD4 + CD25 + Foxp3 + , CD4 + CD25 + Foxp3 + IL17 + and CD8+CD25 T regulatory cells in adipose tissue and in adipose tissue associated stromal vascular cells in a subject suffering of a Metabolic Syndrome or any of the conditions comprising the same.
  • the composition of the invention leads to at least one of a decrease in the serum levels of triglycerides, ALT, AST and Glucose and a decrease in insulin-resistance in a subject suffering of a Metabolic Syndrome or any of the conditions comprising the same.
  • a specific embodiment of the invention relates to the use of the immunoglobulin preparation in preparing a composition for the prevention and/or treatment and prophylaxis of Metabolic Syndrome or any of the .conditions comprising the same, related to or caused by, more particularly, at least one condition of dyslipoproteinemia (hypertriglyceridemia, hypercholesterolemia, low HDL-cholesterol), obesity, NIDDM (non-insulin dependent diabetes mellitus, Type 2), IGT (impaired glucose tolerance), blood coagulability, blood fibrinolysis defects and hypertension.
  • dyslipoproteinemia hyperlipoproteinemia
  • hypercholesterolemia hypercholesterolemia
  • low HDL-cholesterol low HDL-cholesterol
  • obesity non-insulin dependent diabetes mellitus, Type 2
  • IGT impaired glucose tolerance
  • blood coagulability blood fibrinolysis defects and hypertension.
  • an autoimmune disease may be any one of rheumatoid arthritis, diabetes, asthma, acute and chronic graft versus host disease, systemic lupus erythmatosus, scleroderma, multiple sclerosis, inflammatory bowel disease and immune mediated hepatitis.
  • the immunoglobulin preparation used by the invention recognizes and binds at least one antigen specific for the disorder to be treated and modulates immune-regulatory cells, specifically, regulatory T cells.
  • the immunoglobulin preparation of the invention may be directed to antigens that are not specific to the treated disorder.
  • antigens may be any target immune-related components having a modulatory effect on the immune-response.
  • modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance toward a proinflammatory ThI immune response.
  • Activation of ThI cells results in an immune response specifically directed toward the treated disorder.
  • the invention relates to the use of a colostrum-derived, milk or milk product/s-derived immunoglobulin preparation for preparing a composition suitable for preventing and/or treating an immune-related disorder that may be a malignant and non-malignant proliferative disorder, genetic disease, infectious disease and a neurodegenerative disorder.
  • the pro-inflammatory effect of the modulatory composition of the invention may be achieved by either a passive or an active mode of action.
  • the malignant ⁇ proliferative disorder may be any one of solid and non-solid tumor selected ' from the group consisting of carcinoma, sarcoma, melanoma, leukemia, myeloma and lymphoma.
  • the use according to the invention relates to . the preparation of a composition applicable for preventing and/or treating carcinoma, more specifically, any one of hepaotcellular carcinoma, prostate cancer, breast carcinoma, colon carcinoma, and said leukemia is any one of acute and chronic leukemia.
  • the invention provides the use of the immunoglobulin preparation of the invention for preparing composition for the treatment and prophylaxis of a neurodegenerative disorder, for example, a protein misfolding disorder, an amyloid disease, a CNS autoimmune disease, taupathy or a prion disease.
  • a neurodegenerative disorder for example, a protein misfolding disorder, an amyloid disease, a CNS autoimmune disease, taupathy or a prion disease.
  • such disorder may be Alzheimer's disease, Parkinson's disease, ALS (Amyotrophic Lateral Sclerosis), Huntington's disease, Pick's disease, fronto temporal dementia, cortico-basal degeneration, progressive supranuclear palsy, Spongiform encephalopathies, Scrapie, mad cow disease and Bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, Fatal Familial Insomnia, Gerstmann-Straussler-Scheinker syndrome and Kuru.
  • the use according to the invention relates to the preparation of a composition applicable for preventing and/or treating an infectious disease, for example, a disease caused by Clostridium difficile.
  • the use according to the invention is for preparing a composition that may be administered orally or by inhalation as an aerosol or by intravenous, intramuscular, subcutaneous, intraperitoneal, perenteral, transdermal, intravaginal, intranasal, mucosal, sublingual, topical, rectal or subcutaneous administration, or any combination thereof.
  • the invention relates to a method for the treatment and prophylaxis of an immune-related disorder.
  • the method of the invention comprises the step of administering to a subject in need thereof a therapeutically effective amount of mammalian colostrum- derived, milk or milk product/s-derived immunoglobulin preparation or of a composition comprising the same.
  • the immunoglobulin preparation used by the method of the invention or any fragments thereof may recognizes and binds at least one antigen specific for such disorder and therefore may modulate immune-regulatory cells, specifically, regulatory T cells. Such modulation may results for example, in modulation of a Thl/Th2, Trl/Th3 cell balance.
  • Modulation of the Thl/Th2, Trl/Th3 cell balance may activate or alternatively, inhibit an immune response in the treated subject. Such immune response may be specifically directed toward said disorder.
  • the immunoglobulin preparation and the immuno-modulatory composition used by the method of the invention may modulate an immune response in the treated subject in need, either by an active or by a passive manner.
  • this- immunomodulatory effect may be disease specific or non-specific, and therefore may be mediated by activation or promotion of specific subsets of regulatory cells, antigen presenting cells, induction of Th3 cells or TrI cells or any other type of regulatory, effector or suppressor cells via direct or indirect activation of cytokine or chemokines, or any type of cell-cell contact.
  • the immunoglobulin preparation used by the method of the invention may be directed to antigens that are not specific to the treated disorder.
  • antigens may be any target immune-related components having a modulatory effect on the immune- response.
  • the colostrum-derived, milk or milk product/s-derived immunoglobulin preparation or any fragment or mixture, combination, or any composition thereof, used by the method of the invention comprises a monomeric, dimeric and multimeric immunoglobulin selected from the group consisting of IgG, IgA and IgM and any fragments thereof, preparations, mixtures and compositions thereof. More specifically, the immunoglobulin preparation used by the method of the invention may specifically comprise IgG, particularly, IgGl and/or IgG2 and any fragments thereof. Alternatively or additionally, the immunoglobulin preparation used by the method of the invention may specifically comprise secretory dimeric IgA.
  • the method of the invention may use a composition comprising colostrum- derived immunoglobulin preparation.
  • such composition optionally further comprises colostrum component/s, preferably, alarmins, defenensins, colostrinin, or any glycolipids, carbohydrates or any preparations, mixtures and combinations thereof, or any other adjuvant/s.
  • the present invention further provides the use of colostrum or any colostrum-derived preparations for enhancing an immunomodulatory effect of an immunomodulatory therapeutic agent.
  • the composition used by the method of the invention may comprise any additional adjuvant.
  • Appropriate adjuvants therefore may be any antigen, antibody, glycosphingolipids, proteins, cytokines, adhesion molecules, and component that can activate or alter the function of antigen presenting cell or of any other cell related to the immune system in a direct and indirect manner.
  • the immunoglobulin preparation may be obtained from a mammal, preferably a cow, immunized with at least one antigen or a mixture of at least two antigens specific for a disorder to be treated.
  • the immunoglobulin preparation used by the method of the invention recognizes and binds at least one antigen specific for said disorder and modulates immune- regulatory cells, specifically, regulatory T cells.
  • Such modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance toward an anti-inflammatory Th2, Trl/Th3 immune response an immune response specifically directed toward the disorder may be inhibited.
  • method based on inhibition of an immune- response by modulating the Thl/Th2, Trl/Th3 balance towards an antiinflammatory response may be specifically applicable for preventing and/or treating immune related disorder such as Metabolic Syndrome or any of the conditions comprising the same, an autoimmune disease, graft rejection pathology, inflammatory disease, non alcoholic fatty liver disease, hyperlipidemia and atherosclerosis.
  • immune related disorder such as Metabolic Syndrome or any of the conditions comprising the same, an autoimmune disease, graft rejection pathology, inflammatory disease, non alcoholic fatty liver disease, hyperlipidemia and atherosclerosis.
  • an antigen specific for an immune-related disorder used by the method of the invention may be insulin.
  • the colostrum-derived immunoglobulin preparation comprises anti-insulin antibodies.
  • the anti insulin immunoglobulin preparations of the invention clearly promote regulatory T cells accumulation in adipose tissue and in adipose tissue associated stromal vascular cells, in a subject suffering of a Metabolic Syndrome or any of the conditions comprising the same.
  • the colostrum-derived anti-insulin antibodies used by the method of the invention lead to accumulation of CD4 + CD25+Foxp3 + , CD4 + CD25 + Foxp3 + IL17+ and CD8 + CD25 T regulatory cells in adipose tissue and in adipose tissue associated stromal vascular cells in a subject suffering of a Metabolic Syndrome or any of the conditions comprising the same.
  • accumulation of these specific cell subsets in specific organs or tissues is meant that the number or the percentage or the cell population in the particular tissue is elevated or increased in about 5 to 95% as compared to untreated control. More specifically, such increase may be of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or even 99%.
  • the composition used by the method of the invention leads to at least one of a decrease in the serum levels of triglycerides, ALT, AST and Glucose and a decrease in insulin-resistance in a subject suffering of a Metabolic Syndrome or any of the conditions comprising the same.
  • the method of the invention may be used for preventing and/or treating Metabolic Syndrome or any of the conditions comprising the same, for example, at least one of dyslipoproteinemia (hypertriglyceridemia, hypercholesterolemia, low HDL-cholesterol), obesity, NIDDM (non-insulin dependent diabetes mellitus), IGT (impaired glucose tolerance), blood coagulability, blood fibrinolysis defects and hypertension.
  • dyslipoproteinemia hypertriglyceridemia, hypercholesterolemia, low HDL-cholesterol
  • obesity non-insulin dependent diabetes mellitus
  • IGT impaired glucose tolerance
  • blood coagulability blood fibrinolysis defects and hypertension.
  • the method of the invention may be applicable for preventing and/or treating autoimmune disease for example, rheumatoid arthritis, diabetes, asthma, acute and chronic graft versus host disease, systemic lupus erythmatosus, scleroderma, multiple sclerosis, inflammatory bowel disease and immune mediated hepatitis.
  • autoimmune disease for example, rheumatoid arthritis, diabetes, asthma, acute and chronic graft versus host disease, systemic lupus erythmatosus, scleroderma, multiple sclerosis, inflammatory bowel disease and immune mediated hepatitis.
  • the immunoglobulin preparation used by the method of the invention recognizes and binds at least one antigen specific for the specific disorder and modulates immune-regulatory cells, specifically, regulatory T cells.
  • the colostrums-derived immunoglobulin preparation of the invention or the immuno- modulatory composition derived therefrom may act in an . indirect manner by activation or promotion of specific subsets of regulatory cells, or antigen presenting cells, or by any type of cell-cell contact.
  • Such immunoglobulin preparation may be directed towards different components of the immune-system.
  • modulation may results for example, in modulation of the Thl/Th2, Trl/Th3 cell balance toward a pro-inflammatory ThI immune response thereby activating an immune response specifically directed toward the treated disorder.
  • the antigen used may be an antigen non-specific to the treated disorder.
  • an antigen derived from a component of the immune-system may be mediated by activation or promotion of specific subsets of regulatory cells, antigen presenting cells or any type of cell-cell contact via cytokine/s and/or chemokines.
  • the method of the invention may be used for preventing and/or treating an immune-related disorder such as a malignant and non-malignant proliferative disorder, genetic disease, neurodegenerative disorder and an infectious disease.
  • an immune-related disorder such as a malignant and non-malignant proliferative disorder, genetic disease, neurodegenerative disorder and an infectious disease.
  • the method of the invention is intended for preventing and/or treating a malignant proliferative disorder, for example, solid and non-solid tumor selected from the group consisting of carcinoma, sarcoma, melanoma, leukemia, myeloma and lymphoma.
  • a malignant proliferative disorder for example, solid and non-solid tumor selected from the group consisting of carcinoma, sarcoma, melanoma, leukemia, myeloma and lymphoma.
  • the method of the invention may be applicable for preventing and/or treating carcinoma such as hepaotcellular carcinoma, prostate cancer, breast carcinoma, colon carcinoma, and said leukemia is any one of acute and chronic leukemia.
  • the method of the invention may be applicable for preventing and/or treating a neurodegenerative disorder, for example, a protein misfolding disorder, an amyloid disease, a CNS autoimmune disease, taupathy or a prion disease.
  • a neurodegenerative disorder for example, a protein misfolding disorder, an amyloid disease, a CNS autoimmune disease, taupathy or a prion disease.
  • the method of the invention may be applicable . for preventing and/or treating an infectious disease, specifically, an infectious disease caused by Clostridium difficile.
  • the composition may be administered orally or by inhalation as an aerosol or by intravenous, intramuscular, subcutaneous, intraperitoneal, perenteral, transdermal, intravaginal, intranasal, mucosal, sublingual, topical, rectal or subcutaneous administration, or any combination thereof.
  • the method of the invention is specifically suitable for the treatment of a mammalian subject.
  • mammalian for purposes of treatment refers to any animal classified as a mammal including, human, research animals, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc.
  • said mammalian subject is a human subject.
  • treat, treating, treatment means ameliorating one or more clinical indicia of disease activity in a patient having an immune-related disease.
  • Treatment refers to therapeutic treatment.
  • Those in need of treatment are mammalian subjects suffering from an immune -related disease.
  • patient or “subject in need” is meant any mammal for which administration of the immuno modulatory composition of the invention is desired, in order to prevent, overcome or slow down such infliction.
  • the terms “effective amount” or “sufficient amount” mean an amount necessary to achieve a selected result.
  • the “effective treatment amount” is determined by the severity of the disease in conjunction with the preventive or therapeutic objectives, the route of administration and the patient's general condition (age, sex, weight and other considerations known to the attending physician).
  • the dosage of needed to achieve a therapeutic effect will depend not only on such factors as the age, weight and sex of the patient and mode of administration, but also on the degree of disease progression and the potency of the particular derivative being utilized for the particular disorder of disease concerned.
  • Such method may comprise the administration of a prophylactically effective amount of the composition of the invention or of the active ingredients comprised within such composition, to a person at risk of developing a disease.
  • prophylactically effective amount is intended to mean that amount of a pharmaceutical combined composition that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician. It should be noted that for the method of treatment and prevention provided in the present invention, said therapeutic effective amount, or dosage, is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates.
  • dosage is calculated according to body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the composition of the invention in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the composition of the invention is administered in maintenance doses, once or more daily.
  • the invention provides an immunomodulatory combined composition comprising as an active ingredient a combination or mixture of colostrum preparation and immunomodulatory therapeutic agent.
  • the combined composition of the invention may be used for the treatment and/or prevention of immune -related disorders, specifically, Metabolic Syndrome, autoimmune disorders, malignant and non-malignant proliferative disorder, genetic disease, infectious diseases, and neurodegenerative disorders.
  • Hep 3B2.1-7 [Hep 3B; Hep-3B; Hep3B]- Human liver hepatocellular carcinoma cell line; ATCC number HB-8064TM.
  • CCL-224-Colon cancer cells of human origin colon, colorectal adenocarcinoma
  • ATCC number CCL-224TM ATCC number CCL-224TM .
  • PC-3-Prostate cancer- human origin prostate, adenocarcinoma
  • ATCC number CRL-1435 PC-3-Prostate cancer- human origin (prostate, adenocarcinoma); ATCC number CRL-1435.
  • All cell lines are cultured in RPMI 1640 (BEIT HAEMEK - ISRAEL) supplemented with lOO ⁇ g/ml penicillin, lOO ⁇ g/ml streptomycin, 2mM L- glutamin and 10% FCS (BEIT HAEMEK- ISRAEL).
  • mice/Ob mice of the strain B6.V-Lep ⁇ ob>), purchased from The Jackson Laboratory, Bar Harbor, Maine, USA or from Harlan Laboratories (USA).
  • mice *Eleven to twelve week old C57/bl mice obtained from Harlan Laboratories, Ein Karem, POB 12085, Jerusalem 91120, Israel (http://www.harlanisrael.com) . All animals are maintained in the Animal Core of the Hadassah-Hebrew University Medical School. Mice are administered standard laboratory chow and water ad libitum, and kept in 12 -hour light/dark cycles. Animal experiments were carried out according to the guidelines of the Hebrew University-Hadassah Institutional Committee for. Care and Use of Laboratory Animals, and with the committee's approval.
  • Antibodies anti-CD4-Pacific Blue (eBioscience, San Diego, CA). anti-CD8-FITC (eBioscience, San Diego, CA). anti-IL-17-PE (eBioscience, San Diego, CA). anti CD25-PercP-Cy5.5 (eBioscience, San Diego, GA). anti FOX3p PE-Cy725 (eBioscience, San Diego, CA). anti-GDl6/32 (eBioscience, San Diego, CA).
  • Two lysis buffers are prepared, for the cytosolic fraction (buffer 1), and for the membranal fraction (buffer 2).
  • Buffer 1- 2OmM Tris HCl-pH 7.5, 15mM NaCl, and 2mM EDTA.
  • NP-40 detergent also called Igepal CA-630 by Sigma
  • Pre-Sl+ PreS for HBV obtained form VIROSTAT, (Immunochemicals for Infectious Disease Research, POB 8522, Portland, Maine 04104, USA).
  • Pre-Sl+S2 are recombinant antigen including amino acid residues from 1 to 174 of adw pre Sl region. The peptide is fused to terminal 6 histidines. Total molecular weight is 21 kDa.
  • NS3, NS4a+b and NS5 for HCV will be obtained from VIROSTAT (Immunochemicals for Infectious Disease Research, POB 8522, Portland, Maine 04104, USA).
  • NS3 is a recombinant antigen for HCV, comprising the C-terminal 380 amino acid peptide, and having a molecular weight of 68kDa.
  • NS4 is a recombinant antigen for HCV
  • NS4a+b is a peptide comprising amino acid residues from 1658 through 1863, and having a molecular weight of 19kDa. This peptide is fused beta-galactosidase peptide (114 kDa).
  • the total recombinant antigen has a molecular weight of 133kDa.
  • NS5 is a recombinant antigen for HCV and includes the NS5a region fused to GST. The total molecular weight of this antigen is 38 kDa. All recombinant antigens are expressed in E. coli.
  • the toxin is a lyophilized powder of molecular weight of about -270 kDa.
  • amyloid ⁇ protein is a synthetic peptide (lmg) which was purchased from Biosource International (Camarillo, California, USA).
  • Cytosolic fraction and membranal fraction are used as antigens for immunization.
  • Cytosolic fractionation is performed by rinsing the culture dish with 10- 15ml of sterile PBS, lysing cells with 1-1.5ml of lysis buffer 1, scraping and collection of cells into 50ml eppendorff tubes on ice, dividing of the volume collected into 2ml eppendorff tubes, sonication of the cells (5 cycles, 25 . seconds each cycle), followed by centrifugation (at 4°C, 14,000 RPM for 15 minutes), collection of supernatants, sampling (for protein quantification using the Bradford technique), and storage at -20°C.
  • the remaining pellet from the above mentioned centrifugation of the cytosolic fractionation is used for membranal fractionation performed by adding 100-250 ⁇ l of lysis buffer 2, agitating tubes (30 minutes in 4 0 C), centrifuging (at 4°C, 14,000 RPM for 15 minutes), collecting supernatants, sampling (for protein quantification using the Bradford technique), and finally storing until use in -20 0 C.
  • cyosolic and membranal fractions of spleen and peripheral blood cells are used in the preparation of N antigens for immunization.
  • livers After harvesting the livers are transferred to ice cold PBS cut, minced and homogenized using a dounce homogenizer with 9ml of sterile cold lysis buffer 1, divided into eppendorff tubes (1.5ml in each tube), and kept on ice for 30 minutes, followed by sonication (five cycles of 25 seconds) and centrifugation (at 4°C, 14,000 RPM for 15 minutes). The supernatants are collected into one tube, sampled for protein quantification using the Bradford technique and stored at -2O 0 C. Pancreas;
  • pancreases After harvesting the pancreases are transferred to ice cold PBS, cut, minced and homogenized using a dounce homogenizer with 2ml sterile cold lysis buffer 1, divided into eppendorff tubes (1ml in each tube), and kept . on ice for 30 minutes, followed by sonication (five cycles of 25 seconds), and centrifugation (at 4°C, 14,000 RPM for 15 minutes). The supernatants are collected into one tube, sampled for protein quantification using the Bradford technique and stored at -2O 0 C.
  • the spleens are minced on cells dissociation grids (60 mesh) in RPMI 1640 medium, centrifuged (at 4°C, 1,400 RPM for 10 minutes) and the supernatant discarded; Red blood cells are lysed by adding ImI of cold RBC lysis buffer (155mM ammonium chloride), followed by rinsing three times with cold PBS and centrifugation.
  • ImI of cold RBC lysis buffer 15mM ammonium chloride
  • Cold buffer 1 was added to the pellet of spleen cells (in a 6:1 ratio of buffer to pellet) and the cells are divided into 2ml vials, kept on ice for 30 minutes, sonicated five times (25 seconds each time), and centrifuged (at 4°C, 14,000 RPM for 15 minutes); Supernatants are then collected from all vials, sampled for protein quantification, and kept at -20°C.
  • Peripheral blood cells obtained from experimental animals are collected into EDTA containing vials, centrifuged (at 4°C, 1,400 RPM for 10 minutes), and the supernatant discarded; Red blood cells are lysed using
  • Aortic valve lymphocytes are isolated by crushing the valves through a stainless mesh (size 60, Sigma Chemical Co., St Louis, MO, USA). The cell suspension is placed in a 50-mL tube for 3 minutes and washed twice with cold PBS (1250 rpm for 10 minutes), and debris is removed. Cells are re- suspended in PBS, the cell suspension is strained through a nylon mesh presoaked in PBS, and unbound cells are collected. Cells are washed twice in 45 mL PBS. For aortic valve isolation, 20 mL of histopaque 1077 (Sigma Diagnostics, St Louis, MO, USA) is placed underneath cells suspended in 7 mL PBS in a 50-mL tube. The tube is centrifuged at 1640 rpm for 15 minutes at room temperature. Cells at the interface are collected, diluted in a 50-mL tube, and washed twice with ice-cold PBS (1250 rpm for 10 minutes).
  • mice of different experimental models are sacrificed on day 60 of the experiment.
  • Splenic lymphocytes and NKT cells are isolated and red blood cells removed.
  • Intrahepatic lymphocytes are isolated as follows: After cutting the inferior vena cava above the diaphragm, the liver is flushed with cold PBS until it become pale, followed by removal of connective tissue and gall bladder. Livers and spleens were kept in RPMI-1640 + FCS. Then spleens were crushed through a 70 ⁇ m nylon cell strainer (Falcon) and centrifuged (1250 rpm for 7 min) for the removal of cell debris.
  • Falcon 70 ⁇ m nylon cell strainer
  • Red blood cells were lysed with ImI of cold 155mM ammonium chloride lysis buffer and immediately centrifuged (1250 rpm for 3min). Splenocytes were then washed and resuspended with ImI RPMI + FCS. Remains of connective tissue were removed. The viability by trypan blue staining was above 90%.
  • livers were first crushed through a stainless mesh (size 60, Sigma) and the cell suspension was placed in a 50-ml tube for 5min to enable cell debris to descend. 10ml of Lymphoprep (Ficoll, Axis-Shield PoC AS, Oslo, Norway) was slowly placed under the same volume of cell suspension in 50-ml tubes.
  • the tubes were then centrifuged at 1800 rpm for 18min. Cells in the interface were collected and moved to new tubes which were centrifuged again at 1800 rpm for lOmin, to obtain a pellet of cells depleted of hepatocytes to a final volume of 250 ⁇ l. Approximately IxIO 6 cells/mouse liver, were recovered. Cells viability was detected by trypan blue staining.
  • Adipose tissue (visceral fat pads) was minced and incubated in Krebs- Ringer bicarbonate buffer (3 mL/g adipose tissue) containing 10 mM glucose and 2.5% bovine serum albumin, incubated with 840 U/g collagenase type I (Sigma, Rehovot, Israel) at 37 °C with gentle agitation for 1 hour. Then filtered twice through chiffon mesh (100 ⁇ m) and centrifuged 50xg for 5 minutes. Floating adipocytes were then separated from the pellet of stromal vasculature (SV) fraction. The lower fraction was removed and centrifuged at 200xg for 5 min to pellet the SV cells. Cell number was then counted. Flow cytometery analysis (FACS) for determination of different subsets of lymphocytes
  • Cells are isolated using anti-CD3 and anti-CD4, anti-CD8, and anti-NKl.l, respectively. Cells are washed twice in 1% BSA and kept at 4 0 C until reading. For the control group, only 5 ⁇ L of 1% BSA are added. Surface staining was performed by incubating cells with antibodies and anti-CD 16/32 (blocks Fc, eBioscience) at 4°C in FACS buffer containing PBS and 0.5% BSA, for 30 min. Cells were further washed twice with FACS buffer, resuspended in FACS buffer, and analyzed by flow cytometry.
  • Analytical cell sorting is performed on IxIO 4 cells from each group with a fluorescence-activated cell sorter (FACStar Plus, Becton Dickinson). Appropriate isptype controls were used in all experiments. Analysis was performed using a FACSCalibur instrument (Becton Dickinson, San Jose, CA). Only live cells were counted, and background fluorescence from non— antibody-treated lymphocytes was subtracted. Gates were set on forward- and side-scatters to exclude dead cells and red blood cells. Data was analyzed by the Consort 30 two-color contour plot (Becton Dickinson, Oxnard, CA, USA) or Cell Quest programs.
  • NKT lymphocyte percentage FACS analysis for determination of NKT lymphocyte percentage
  • triplicates of 2-5xlO 4 cells/500 ⁇ l PBS are placed into Falcon 2052 tubes, incubated with 4 ml of 1% BSA for 10 minutes, and centrifuged at 350g for 5 minutes.
  • anti-CD3 and anti DX5 antibodies are used (Pharmingen, USA).
  • Analytical cell sorting is performed on 1x10 4 cells from each group with a fluorescence-activated cell sorter (FACSTAE plus,. Becton Dickinson). Only live cells are counted, and background fluorescence from non-antibody-treated lymphocytes ' is subtracted. Gates are set on forward- and side-scatters to exclude dead cells and red blood cells. Data is analyzed with the Consort 30 two-color contour plot program (Becton Dickinson, Oxnard, CA), or the CELLQuest 25 program.
  • Cell separation is performed using Magnetic Cell Sorting (MACS, Miltenyi Biotec, Germany) according to the manufacturer's instructions.
  • Anti- CD 3 and anti- DX5 magnetic beads are used for separation of NKT lymphocytes; anti-CD lie beads served for separation of dendritic cells. Beads are removed between the two steps according to the manufacturer's instructions. Above 95% accuracy is achieved by FACS analysis of cells.
  • Serum IFN ⁇ , ILlO and IL4 levels will be measured by a "sandwich” ELISA method using Genzyme Diagnostic kits (Genzyme Diagnostics, MA, USA), according to manufacturer's instructions.
  • splenocytes are lysed in lOO ⁇ l of lysis solution (Sigma). Proteins (lOO ⁇ g/lane) are resolved by electrophoresis on SDS- polyacrylamide (7.5%) gels, and electroblotted to nitrocellulose membranes (Schleicher & Schuell, Germany).
  • AST serum aspartic transaminase
  • ALT alanine aminotransferase
  • mice blood glucose, total cholesterol and triglyceride.
  • Blood glucose values were measured with a standard glucometer.
  • Plasma triglyceride and total cholesterol values were measured by a clinical chemistry analyzer Reflovet Plus machine (Roche Diagnostics, GmbH, Mannheim, Germany).
  • mice were subjected to a glucose tolerance test (GTT) on day 30 after overnight fasting.
  • GTT glucose tolerance test
  • Glucose was administered orally (1.25 g per kg).
  • Serum glucose measurements were performed on tail-vein blood every 15 minutes for 3 hours.
  • Glucose levels were measured by a standard glucometer.
  • IFN- ⁇ and TGF- ⁇ levels were determined on serum by "sandwich” ELISA, using commercial kits (Quantikine, R&D Systems, Minneapolis, MN, USA). Serum insulin was also determined by "sandwich” ELISA, using the commercial kit of Mercodia AB (Uppsala, Sweden) according to the manufacturer's instructions.
  • mice undergo magnetic resonance imaging (MRI) on day 60. Liver size is assessed, and hepatic fat content is measured by a double-echo chemical shift gradient-echo sequence technique, that provides in-phase and out-of- phase images in a single acquisition for assessment and quantification of liver fat.
  • Tl -weighted out-of -phase MR imaging is sensitive for detection of relatively small proportions of tissue fat.
  • MR images are acquired by a 1.5- T system (Signa LX;GE, Milwaukee, USA). Double-echo MR imaging is performed with a repetition time (TR) of 125 msec, double echo times (TEs) of 4 and 6.5 msec, and a flip angle of 80°.
  • SII SI index
  • SIip-Siop SIip
  • SIip in- phase SI
  • MFI liver area*SII
  • a liver segment from each mouse was fixed in 10% formaldehyde and embedded in paraffin for histological analysis.
  • Five sections (5 ⁇ m) are stained with hematoxylin/eosin and reviewed by two pathologists in a blinded fashion. Histological examination and the steatohepatitis grade scoring (NASH score) are performed using the steatohepatitis scoring system
  • GVHD is assessed by the degree of weight loss, general appearance and a skin score based on a scale of cutaneous changes (including hair loss, skin desquamation and skin thickening) ranging from 0 (no GVHD) - 4 (maximal GVHD). Scale of cutaneous changes is assessed in five selected areas: forehead, periorbital, auricles, back and tail.
  • B10.D2 splenocytes (IxIO 6 ) from mice fed with Balb/c splenocytes, B10.D2 splenocytes, bovine serum albumin and regular chow is cultured in flat bottom microwell plates (Sterilin cat. n. M29ARTL) with irradiated (30 Gy) Balb/c or C57BL/6 spleen cells (2xlO 6 ) in a total volume of 0.2 ml RPMI 1640 culture medium, supplemented with lOO ⁇ g/ml penicillin, 100 ⁇ g/ml streptomycin, 2 mM L-glutamine, with 5xlO" 5 2M-ME and 10% FCS.
  • Serum AST and ALT levels are measured by an automatic analyzer as indicated for the Metabolic Syndrom animals.
  • Hematoxylin/eosin staining of paraffin-embedded liver sections is performed. Sections are examined by two experienced pathologists (VD, YS) that are blinded to the experiment conditions.
  • Bl 6 melanoma cells are cultured in flat bottom microwell plates (Sterilin) in 3 concentrations: 50,000, 100.000 and 200.000 cells/well. Different concentrations of tested antibodies are added to appropriate wells, PBS is added to control wells. 5 hours later l ⁇ mCi of 3H TdR (5 Ci/nmol, Nuclear Research Center, Negev, Israel) was added to all wells. After 24 hours in a 37 0 C, humidified 5% CO2 incubator, cells are collected on paper filters using a multiple sample harvester (Titertek Cell Harvester 530; Flow Laboratories. McClean, VA 22102). Radioactivity is measured by a liquid scintillation counter.
  • B16 melanoma cells are cultured in flat bottom microwell plates (Sterilin) in 3 concentrations: 50,000, 100.000 and 200.000 cells/well. Different concentrations of tested antibodies are added to appropriate wells, PBS is added to control wells. After 24 hours in a 37 0 C humidified 5% CO2 incubator, cells are tripsynised and dyed with Tripan Blue. Dead cells are counted using light microscope. Apoptosis assay
  • Apoptosis is assayed using the Annexin-V-FLUOS Staining Kit.
  • mice are administered standard laboratory chow and water ad libitum, kept in 12-hour light/dark cycles and injected with IxIO 6 leukemia Bell cells.
  • mice hepatocellular carcinoma- Balb/C male mice are administered standard laboratory chow and water ad libitum, and kept in 12-hour light/dark cycles. Mice are injected s.c. with IxIO 7 Hep3b cells.
  • mice are injected s.c. with 1 x 10 6 B16-WT, B16-CDld or B16-1C3 cells.
  • Example 1
  • Two dairy cows are immunized with a mixture of antigens.
  • the antigens vaccine was administered during the last eight weeks of gestation.
  • Colostral milk was collected during the first two days of lactation. The milk fat was removed and skim milk was pasteurized at 56° C for 30 minutes and then coagulated by renetting as in Hilpert, Human Milk Banking 1984. After removal of milk curd containing casein, the whey was centrifuged and the fine precipitate was discarded.
  • the precipitate was dissolved in 0.01M TRIS-HCl buffer pH 8 containing 0.32M NaCl (30% of original volume). This solution was extensively dialyzed against five volumes of the same buffer using an Amicon spiral membrane SIY30 cartridge. The antibody solution was then concentrated to 10%, snap frozen and freeze dried. ⁇
  • Antibody fragments are prepared according to modified method based on the methods described by Jones R.G.A. and Landon J. [Jones R.G.A. and Landon J. J. Immunol. Methods 263: 57-74 (2002)]. Briefly, an equal volume of 0.2M Sodium Acetate buffer pH 4.0, is added to a colostrum pool obtained from immunized animals as described above. The pH of the diluted colostrum pool has been adjusted to 4.6 and incubated at 37 0 C for two hours to precipitate caseins. Subsequently, colostrum is centrifuged and filtered (0.45 ⁇ m) to remove casein.
  • the pH of the resultant colostral Whey has been adjusted to pH 4.0, followed by addition of Pepsin (Enzyme Solutions with 1:15,000 activity) at 5.0% w/w and incubation for twenty hours at 45°C. Pepsin digestion has been stopped by addition of 0.5 vol. of IM Tris pH8 and cooling the reaction mix to 4°C. The pH of the reaction is adjusted to pH to 7.0 and the F(ab')2 mix is concentrated using 3OkD ultra-filtration membrane and dia-filtrate vs. >50 volumes of 2OmM sodium phosphate/15OmM NaCl pH 6.0 buffer.
  • Fab 1 50ul (1/9 vol.) of 0.1M 2-mercaptoethylamine (MEA) in 0.1M sodium phosphate buffer pH 6.0, containing freshly prepared 5mM EDTA-disodium, are added to 0.1-3.0 mg of F(ab')2 in 0.45ml of 0.1 M sodium phosjphate buffer, pH 6.0. The mixture is then incubated at 37°C for 90mins. Subsequently, the reaction mixture is applied on a PD-10 column, or a suitable G25 column, to remove the excess MEA. 0.1M sodium phosphate (pH 6.0, with 5mM EDTA-disodium) is used as the running buffer. The first protein peak which contains Fab', is collected and used for treating the corresponding different indications as indicated herein below.
  • MEA 2-mercaptoethylamine
  • colostrum was collected from approximately 200 cows and frozen in individual bags for 19 testing. For processing, colostrum was thawed, pooled and fat was removed. Each batch was pasteurized. Colostrum was concentrated by ultra-filtration to reduce volume before freeze drying. The ultra-filtration step reduced lactose in the final powder to less than 7% (from about 50%). Two freeze dried bovine-colostrum powders were used. These included colostrum derived solution (CDS) which contained insulin antibodies.
  • CDS colostrum derived solution
  • This preparation was a mixture of colostrums originated from 3 cows which were vaccinated with Insulin A (Insulin conjugated to KLH), batch no. 100908. The colostrum powder was made up into a milky suspension by adding it to water.
  • Ob/Ob mice 7-8 weeks of age were divided into seven groups as detailed in Table 2. Mice were fed according to group allocation for 25 days and then sacrificed. Groups A and B were treated with colostrum derived solution (CDS) enriched with anti-insulin antibodies (anti-insulin specific, AIS- CDS). This preparation was a mixture of colostrums originated from 3 cows which were vaccinated with Insulin A (Insulin conjugated to KLH), batch no. 100908. The colostrum powder was made up into a milky suspension at low and high dosages [10-30 ⁇ g/ml (A) and 1000 ⁇ g/ml (B), w/v, respectively].
  • CDS colostrum derived solution
  • AIS- CDS anti-insulin specific
  • CDS purified anti insulin specific, PAIS-CDS
  • PAIS-CDS purified anti insulin specific, PAIS-CDS
  • NAIS-CDS non anti insulin specific CDS
  • Group G consisted of untreated controls which received PBS.
  • mice Effect of oral administration of anti insulin antibodies on regulatory T cells
  • AIS-CDS anti insulin colostrum derived antibodies
  • PAIS-CDS purified anti-insulin antibodies
  • mice seven experimental groups as described above were fed according to the indicated diets. After 25 days the mice were sacrificed and lymphocytes were isolated from adipose and stromal vasculature (SV) tissues, livers and spleens. The distribution of the different subsets of regulatory T cells in the tissues was analyzed by FACS. The . results for groups B and D are presented in Table 3 as ratio versus control Group G.
  • IL 17 was suggested to play a role in the metabolic syndrome [Filippi, CM. et al., Diabetes 57:2684-92 (2008)].
  • FoxP3+ILl7+ cells have not been previously studied.
  • An increase in a subset of CD4+CD25+FOXP3+IL17+ cells in the adipose tissue, SV and liver was noted in mice in both groups B and D, while this population decreased in the spleen of group D.
  • the proportion of CD4+CD25+FOXP3+IL17+ lymphocytes as calculated by FACS in the adipose tissue versus the spleen was much higher in groups B and D versus G (5.46 and 16.14 vs. 4.68, for groups B, D, and G, respectively).
  • the data supports an organ specific effect, for the accumulation of this subset of Tregs in the adipose tissue.
  • CD8+CD25+ and CD8+FoxP3+ cells were suggested to play a regulatory role in diabetes.
  • Table 3 colostrum derived anti insulin antibodies (AIS) and purified anti insulin specific (PAIS-CDS) induced expansion of these two populations in all examined tissues of both groups B and D, except for in the liver of AIS fed mice of group B, in which a decrease in CD8+CD25+ cells was observed.
  • AIS colostrum derived anti insulin antibodies
  • PAIS-CDS purified anti insulin specific
  • mice in group B receiving AIS-CDS, had a higher proportion of CD4+CD25+Foxp3+ lymphocytes in the adipose tissue and SV as compared to group D. A significant increase was also seen in the proportion. of CD8+CD25+ cells.
  • the data suggest that the adjuvant effect of the colostrum in group B has an effect on the distribution of Tregs leading to the accumulation of these two populations in the adipose tissue and SV.
  • mice fed with anti insulin antibodies in low and high dose mice fed with anti insulin antibodies in low and high dose.
  • mice fed with purified anti insulin antibodies (groups C and D), and untreated controls (group G) underwent glucose tolerance test every 15 days.
  • both AIS-CDS (groups A, B) and PAIS-CDS (groups C, P) improved glucose tolerance demonstrated by lower glucose values at glucose tolerance test (p ⁇ 0.01) with a decrease in the area under the curve (AUC) by more than 40%, as compared to the control group G (23962.5, 32589, 23818.7 and 23355 in groups A, B, C and D vs. 42448.7 in control group G).
  • mice of the different groups were tested for fasting serum glucose levels on a weekly basis.
  • Figure 2C presents the decrease in mean fasting serum glucose levels. A high effect was noted for mice in groups A and B, orally administered with AIS-CDS, versus mice in groups C and D, fed with PAIS-CDS, or control mice in groups E and G.
  • FIG. 2D shows the effect on the mean reduction of glucose levels per week for each experimental group. The highest glucose levels reduction is clearly demonstrated in groups A and B fed with AIS-CDS, compared to groups C and D, fed with PAIS-CDS and control groups E and G.
  • Figure 4A shows that among the study groups treated with AIS-CDS and PAIS-CDS, none of the groups differed significantly from the control group in neither the initial nor the final body and liver weights. As shown in Figure 4B, no changes in liver/body weight ratio were demonstrated in any of the groups.
  • the inventors searched for further disease-derived antigens in order to study the effect of the colostrum-derived compositions of the invention upon metabolic disorders. Therefore, both, the leptin deficiency model of leptin- deficient Ob/Ob mice and the diabetic Passamon model of desert sand rats (Psammomys obesus) are used.
  • the desert sand rat a model of nutritionally-induced type II diabetes, develops severe metabolic disorders such as significant hyperinsulinemia, hyperglycemia and hypertriglyceridemia when fed on a high-energy diet.
  • liver and pancreas of sacrificed mice and rats are used for the preparation of antigenic mixtures for immunizing cows for production of specific antibodies against antigens originated from metabolic syndrome models. After, harvesting liver and pancreas are transferred and antigens are prepared for use in the creation of antibodies as described in experimental procedure. Antibodies specifically recognizing antigens prepared from animals of the Metabolic Syndrome model, are prepared and purified as described in Example 1 above.
  • colostrum-derived E.coli specific antibodies were used. Therefore, ten mice (naive), age 11-12 weeks were fed for 7 days with PBS (A) or with colostrum enriched with antibodies to E CoIi. (B), [100mg/ml, diluted in DDW and warmed for 1-2 hours at 37 0 C before administered to mice]. FACS analysis was preformed for different regulatory T cells. As presented by Tables 5 and 6, administration of colostrum enriched antibodies resulted in clear effect on several cell populations including CD45+LAP+ CD25+CD4+LAP and CD25" CD4 + LAP+.
  • mice Eight to ten weeks old male Balb/C mice are I.V (tail vein) injected with a total volume of 0.2ml/mouse of 1 x 10 6 BcI 1 leukemic cells.
  • White blood cells (WBC) are counted in blood samples taken every other day from the Plexus Orbital using a 20 ⁇ l pipette. When WBC count reached a level of 1 x 10 8 /ml, mice are sacrificed and the spleen excised. After excision of spleens and the collection of peripheral blood cells cytosolic and membranal preparations are prepared for use as antigens in the creation of antibodies as described in Experimental Procedure.
  • Antibodies specifically recognizing antigens prepared from animals of the leukemia model are prepared and purified as described in Example 1.
  • mice injected with Bell leukemia cells are orally administered using different concentrations and preparations of specific antibodies as compared to untreated controls. Animals of all tested groups are followed for 48 days for signs of chronic GVHD, leukemia progression and survival as detailed in Experimental procedures. Leukemia is assessed by white blood cell counts (WBC counts > 20 x 10 9 /L is considered leukemic) and spleen size. Tolerance induction in donor mice towards the minor histocompatibility antigens of recipient Balb/c mice is evaluated by one-way mixed lymphocyte reaction (MLR) tests as described in Experimental procedures.
  • MLR mixed lymphocyte reaction
  • Cytosolic and membranal fraction of HuH-7 and Hep3b cells are prepared and. antigens for the creation of antibodies, are prepared as described in Experimental Procedure. Antibodies specifically recognizing antigens prepared from animals of the hepaotcellular carcinoma model are prepared and purified as described in Example 1.
  • mice treated with a specific antibody recognizing antigens obtained from hepaotcellular carcinoma models and control animals treated with nonspecific antibodies or with PBS are monitored for about 3-6 months. Biweekly measurements of tumor volume and body weight are performed and compared in all experimental groups.
  • Antibodies specifically recognizing antigens prepared from animals of the hepatitis model are prepared and purified as described in Example 1.
  • AST serum aspartate aminotransferase
  • ALT alanine aminotransferase
  • histological examination of liver specimens FACS analysis of intrahepatic and intrasplenic lymphocytes for NKT markers, measurement of serum cytokine levels and Western blot analysis for the expression of the transcription factors STAT 1, 4 and 6 and NFKB and are compared to control groups.
  • Antigens for immunization are prepared from cytosolic and membranal fractions of B-16 cell line as described in Experimental procedures.
  • Antibodies specifically recognizing antigens prepared from animals of the melanoma model are prepared and purified as described in Example 1. Use of specific antibodies in the treatment of melanoma:
  • the immunomodulatory effect of the colostrum-derived antibodies is first evaluated in vitro by proliferation assay, Killing assay and apoptosis as described in Experimental procedures.
  • Tumor volume is calculated based on two measures of the two largest diameters, or number of metastasis in the lung. All experimental groups are further monitored for their effect on alteration of lymphocyte subset distribution, cytokine response, determination of NKT lymphocyte percentage and expression of STAT proteins as described in Experimental procedures.
  • amiloid beta is used as an antigen.
  • Antibodies specifically recognizing the amyloid beta antigen are prepared and purified as described in Example 1.
  • AD Alzheimer disease
  • Transgenic mice expressing a mutation in the amyloid precursor protein (APP) and in the presenilinl gene is used as AD model by the inventors.
  • Mice are treated with different concentrations of AD -specific colostrum-derived antibodies of the invention in different modes of delivery such as, drinking water, gavage, and i.p. injection, as compared to untreated controls.
  • the treated animals are . then evaluated for improvement in clinical parameters, including brain amyloid plaques formation.
  • Cytosolic and membranal fractions of CCL-224 and HT29 are used for preparing antigens as described in Experimental procedures.
  • Antibodies specifically recognizing colon carcinoma antigens are prepared and purified as described in Example 1.
  • Cytosolic and membranal fractions of pc-3, Du-145, LN-Cap, TSU-PrI cells will be used for preparing antigens as described in Experimental procedures.
  • Antibodies will be prepared and purified as described in Example 1.
  • mice injected with pc-3, Du-145, LN-Cap, TSU- PrI cells, are orally administered using different concentrations and preparations of specific antibodies as compared to untreated controls. Tumours are measured by calliper every other day. Mice are sacrificed three weeks after being inoculated with prostate cancer cells, tumors are excised, weighed and compared to untreated controls.
  • Antibodies to different cells, MBP, and cytokines are tested.
  • EAE Experimental autoimmune encephalomyelitis
  • myelin associated antigens such as myelin oligodendrocyte glycoprotein (MOG), or proteolipid protein (PLP), emulsified in CFA and followed by a booster with Bordetella pertussis.
  • MOG myelin oligodendrocyte glycoprotein
  • PLP proteolipid protein
  • Clinical assessment of EAE is performed in all experimental groups according to the following criteria: 0, no disease; 1, decreased tail tone; 2, hindlimb weakness or partial paralysis; 3, complete hindlimb paralysis; 4, front and hindlimb paralysis; 5, moribund state.
  • Antibodies to various cytokines and glycolipids are prepared as described in Example 1.
  • Antibodies to collagen or to TNF are prepared as described in Example 1.
  • Adjuvant Arthritis is induced in Lewis rats by injection with 1 mg of Mycobacterium Tuberculosis H37Ra (Difco, Detroit, MI) in Complete Freund 's Adjuvant (Difco) subcutaneously at the base of the tail. Rats are orally administered with different concentrations and preparations of the specific antibodies as compared to untreated controls. Severity of Arthritis (arthritis index) is assessed blindly as follows: 0 - no arthritis; 1 — redness of the joint; 2 — redness and swelling of the joint. The ankle and tarsal-metatarsal joints of each paw are scored. A maximum score of 16 can be obtained, but a score above 8 indicates a severe disease.
  • Antibodies to various cytokines, cells, LDL, different lipids are prepared according to Example 1.
  • mice of all tested groups are sacrificed after 18 weeks and parameters including body weight, plasma total cholesterol, triglycerides, HDL cholesterol (not pooled), serum cytokine levels, FACS analysis of CD4, CD8, NKT (CD3+NK1.1, CD4+NK1.1, CD8+NK1.1) in spleen and liver and examination of STATl- 6 and NFk ⁇ expression in splenocytes, were compared to untreated controls. All tested groups are further monitored for atherosclerotic plaque lesion size (aortic sinus), atherosclerotic plaque distribution and Liver pathology. T cell proliferation response towards ox-LDL is also analyzed and compared to control untreated animals.
  • Toxin A for Clostridium diffeicile is obtained from Sigma (Cat number
  • the toxin is a lyophilized powder of molecular weight of about
  • Antibodies are prepared and purified as described in Example

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions immunomodulatrices comprenant une préparation d’immunoglobuline à base de colostrum de mammifère et éventuellement d’autres colostrums, de lait ou d’un/de plusieurs constituant(s) laitier(s) et d’adjuvants quelconques pour le traitement de troubles d’origine immunologique. Plus spécifiquement, l’invention concerne des compositions comprenant des préparations d'immunoglobuline anti-insuline à base de colostrum pour le traitement du syndrome métabolique. L’invention concerne en outre des procédés et des utilisations des compositions immunomodulatrices pour une immunisation active ou passive, de manière non spécifique ou spécifique des antigènes responsables de maladies.
PCT/IL2009/000273 2008-03-13 2009-03-11 Compositions immunomodulatrices pour le traitement de troubles d’origine immunologique WO2009113065A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2009222965A AU2009222965B2 (en) 2008-03-13 2009-03-11 Immuno-modulating compositions for the treatment of immune-mediated disorders
CA2718381A CA2718381A1 (fr) 2008-03-13 2009-03-11 Preparation d'immunoglobuline derivee du colostrum renfermant des anticorps anti-insuline destines au traitement de syndrome metabolique
NZ587901A NZ587901A (en) 2008-03-13 2009-03-11 Immuno-modulating compositions for the treatment of immune-mediated disorders
EP09720973.8A EP2268669B1 (fr) 2008-03-13 2009-03-11 Colostrum bovin comprenant des anticorps anti-insuline pour le traitement des maladies du trouble métabolique.
DK09720973.8T DK2268669T3 (da) 2008-03-13 2009-03-11 Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme
US12/879,129 US20110200610A1 (en) 2008-03-13 2010-09-10 Immuno-Modulating Compositions for the Treatment of Immune-Mediated Disorders
US13/715,371 US20130164302A1 (en) 2008-03-13 2012-12-14 Immuno-Modulating Compositions for the Treatment of Immune-Mediated Disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3622708P 2008-03-13 2008-03-13
US61/036,227 2008-03-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/879,129 Continuation-In-Part US20110200610A1 (en) 2008-03-13 2010-09-10 Immuno-Modulating Compositions for the Treatment of Immune-Mediated Disorders

Publications (1)

Publication Number Publication Date
WO2009113065A1 true WO2009113065A1 (fr) 2009-09-17

Family

ID=40875006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000273 WO2009113065A1 (fr) 2008-03-13 2009-03-11 Compositions immunomodulatrices pour le traitement de troubles d’origine immunologique

Country Status (7)

Country Link
US (2) US20110200610A1 (fr)
EP (2) EP3231816A1 (fr)
AU (1) AU2009222965B2 (fr)
CA (1) CA2718381A1 (fr)
DK (1) DK2268669T3 (fr)
NZ (1) NZ587901A (fr)
WO (1) WO2009113065A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012023051A2 (fr) 2010-08-17 2012-02-23 Immuron Ltd. Préparation d'immunoglobuline enrichie en anti-lps, destinée à être utilisée dans le traitement et/ou la prophylaxie d'un trouble pathologique
ITMI20102260A1 (it) * 2010-12-09 2012-06-10 Bionest Ltd Gel polifunzionale contro la secchezza vaginale ad effetto diretto e ritardato
WO2012136534A3 (fr) * 2011-04-05 2012-11-29 Mat-Malta Advanced Technologies Limited Utilisation d'un agent sélectionné parmi des anticorps et/ou des antagonistes du facteur de croissance analogue à l'insuline
ITMI20112435A1 (it) * 2011-12-30 2013-07-01 Bionest Ltd Profilassi e terapia delle malattie autoimmuni con citochine e fattori di crescita, antibatterici e anticorpi, isolati dai tessuti e dai liquidi biologici dei mammiferi
WO2013173874A2 (fr) 2012-05-23 2013-11-28 Omniblend Innovation Pty Ltd Composition et procédé pour prise en charge du diabète ou du pré-diabète
WO2016166246A1 (fr) * 2015-04-17 2016-10-20 Mat-Malta Advanced Technologies Limited Biomarqueurs prédictifs de la réponse clinique à un traitement par immunoglobuline anti-lps
US10117930B2 (en) 2009-04-27 2018-11-06 Immuron Limited Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder
EP3452064A4 (fr) * 2016-05-06 2019-11-27 Hadasit Medical Research Services And Development Colostrum hyperimmun utilisé dans la modulation et le traitement d'affections associées au microbiome des mammifères

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011332053B2 (en) 2010-11-23 2016-06-02 Pantheryx, Inc. Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
US8926980B2 (en) * 2011-07-11 2015-01-06 Camas Incorporated Compositions against bacterial toxins
US10464998B2 (en) * 2013-10-30 2019-11-05 Hadasit Medical Research Services And Development Limited Anti-LPS enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
CA3083315A1 (fr) * 2017-11-24 2019-05-31 Defensin Therapeutics Aps Prevention et traitement de la reaction du greffon contre l'hote avec des defensines
CN109010367A (zh) * 2018-08-21 2018-12-18 姜伟 牛初乳粉及其制备方法、制剂和在制备治疗肿瘤药物中的应用
WO2020176637A1 (fr) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions pour la gestion de troubles du tractus gastro-intestinal
AU2020310953A1 (en) * 2019-07-09 2022-02-17 Aquero Canada Ltd. Compositions, processes of production, sterilization, and health-promoting uses of lyophilized milk
WO2022103871A1 (fr) * 2020-11-10 2022-05-19 Wyomingv Immune, Inc. Compositions thérapeutiques pour le traitement de la covid-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087331A1 (fr) * 2000-05-19 2001-11-22 Sergey Georgievich Morozov Produits pharmaceutiques destines a la suppression de troubles auto-immuns au moyen de fragments liant les idiotypes des anticorps anti-idiotypiques
WO2005048935A2 (fr) * 2003-11-14 2005-06-02 Brigham And Women's Hospital, Inc. Methodes pour moduler l'immunite

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572220A (en) * 1976-10-07 1980-07-30 Mochida Pharm Co Ltd Immunochemical process of measuring physiologically active substances
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
JP2879947B2 (ja) * 1990-06-04 1999-04-05 鐘紡株式会社 毛髪改質剤
US5369009A (en) * 1992-04-17 1994-11-29 Dana Farber Cancer Institute Antibodies for P-glycoprotein encoded by the mdr1 gene and uses thereof
EP0725789B1 (fr) 1993-09-20 2003-03-19 Anadis Ltd. Procede d'extraction d'immunoglobulines du colostrum et emploi de ces dernieres dans des preparations pharmaceutiques
US6436401B1 (en) * 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
CA2437099A1 (fr) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Procedes et compositions destines au traitement de dysfonctions immunitaires
KR20100137015A (ko) 2002-03-21 2010-12-29 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물, 제조 및 치료 방법
IL165300A0 (en) 2002-05-21 2005-12-18 Anadis Ltd Method of prophylaxis of infection
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
US20090169566A1 (en) 2004-11-22 2009-07-02 Anadis Ltd. Bioactive compositions
US8071101B2 (en) * 2005-11-03 2011-12-06 Avaxia Biologics, Inc. Antibody therapy for treatment of diseases associated with gluten intolerance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087331A1 (fr) * 2000-05-19 2001-11-22 Sergey Georgievich Morozov Produits pharmaceutiques destines a la suppression de troubles auto-immuns au moyen de fragments liant les idiotypes des anticorps anti-idiotypiques
WO2005048935A2 (fr) * 2003-11-14 2005-06-02 Brigham And Women's Hospital, Inc. Methodes pour moduler l'immunite

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 2002-066650, XP002538617, MOROZOW ET AL.: "Composition for treating autoimmune diseases, e.g. diabetes, comprises immunochemical analogs of the antigens that are the target of teh autoimmune reactions" *
EBINA T ET AL: "Treatment of multiple sclerosis with anti-measles cow colostrum", MEDICAL MICROBIOLOGY AND IMMUNOLOGY, SPRINGER, DE, vol. 173, no. 2, 1 September 1984 (1984-09-01), pages 87 - 93, XP009120465, ISSN: 0300-8584 *
HE F ET AL: "Modulation of human humoral immune response through orally administered bovine colostrum", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 31, no. 2, 1 August 2001 (2001-08-01), pages 93 - 96, XP008102760, ISSN: 0928-8244, [retrieved on 20010712] *
JANUSZ M ET AL: "Effect of a proline-rich polypeptide on IgG level in Chickens", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, POLISH ACADEMY OF SCIENCES, WROCLAW, PL, vol. 44, no. 1, 1 January 1996 (1996-01-01), pages 23 - 26, XP009120466, ISSN: 0004-069X *
SLUKVIN I I ET AL: "B-cell promoting activity of human colostrum", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRINGER, US, vol. 371A, 1 January 1995 (1995-01-01), pages 153 - 157, XP009120570, ISSN: 0065-2598 *
SRIRAM S ET AL: "IN-VIVO IMMUNOMODULATION BY MONOCLONAL ANTI-CD4 ANTIBODY II. EFFECT OF T CELL RESPONSE TO MYELIN BASIC PROTEIN AND EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS", JOURNAL OF IMMUNOLOGY, vol. 141, no. 2, 1988, pages 464 - 468, XP002538612, ISSN: 0022-1767 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117930B2 (en) 2009-04-27 2018-11-06 Immuron Limited Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder
WO2012023051A3 (fr) * 2010-08-17 2012-04-26 Immuron Ltd. Préparation d'immunoglobuline enrichie en anti-lps, destinée à être utilisée dans le traitement et/ou la prophylaxie d'un trouble pathologique
WO2012023051A2 (fr) 2010-08-17 2012-02-23 Immuron Ltd. Préparation d'immunoglobuline enrichie en anti-lps, destinée à être utilisée dans le traitement et/ou la prophylaxie d'un trouble pathologique
US9943597B2 (en) 2010-08-17 2018-04-17 Immuron Limited Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
AU2011340757B2 (en) * 2010-12-09 2016-10-27 Zambon S.P.A. Multipurpose gel for vaginal dryness with direct and delayed effect
ITMI20102260A1 (it) * 2010-12-09 2012-06-10 Bionest Ltd Gel polifunzionale contro la secchezza vaginale ad effetto diretto e ritardato
WO2012076409A1 (fr) * 2010-12-09 2012-06-14 Zambon S.P.A. Gel à buts multiples contre la sécheresse vaginale présentant un effet direct et prolongé
EA026198B1 (ru) * 2010-12-09 2017-03-31 Замбон С.П.А. Универсальный гель против сухости влагалища с прямым и отсроченным эффектом
WO2012136534A3 (fr) * 2011-04-05 2012-11-29 Mat-Malta Advanced Technologies Limited Utilisation d'un agent sélectionné parmi des anticorps et/ou des antagonistes du facteur de croissance analogue à l'insuline
US9801938B2 (en) 2011-04-05 2017-10-31 Mat-Malta Advanced Technologies Limited Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
US9913904B2 (en) 2011-04-05 2018-03-13 Ignova Gmbh Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
ITMI20112435A1 (it) * 2011-12-30 2013-07-01 Bionest Ltd Profilassi e terapia delle malattie autoimmuni con citochine e fattori di crescita, antibatterici e anticorpi, isolati dai tessuti e dai liquidi biologici dei mammiferi
WO2013173874A2 (fr) 2012-05-23 2013-11-28 Omniblend Innovation Pty Ltd Composition et procédé pour prise en charge du diabète ou du pré-diabète
WO2016166246A1 (fr) * 2015-04-17 2016-10-20 Mat-Malta Advanced Technologies Limited Biomarqueurs prédictifs de la réponse clinique à un traitement par immunoglobuline anti-lps
CN107889490A (zh) * 2015-04-17 2018-04-06 维尔茨堡尤利乌斯-马克西米利安大学 抗lps免疫球蛋白治疗的临床应答的预测性生物标志物
EP3452064A4 (fr) * 2016-05-06 2019-11-27 Hadasit Medical Research Services And Development Colostrum hyperimmun utilisé dans la modulation et le traitement d'affections associées au microbiome des mammifères

Also Published As

Publication number Publication date
AU2009222965B2 (en) 2014-10-02
EP2268669A1 (fr) 2011-01-05
NZ587901A (en) 2012-11-30
EP3231816A1 (fr) 2017-10-18
AU2009222965A1 (en) 2009-09-17
US20110200610A1 (en) 2011-08-18
CA2718381A1 (fr) 2009-09-17
EP2268669B1 (fr) 2017-10-18
DK2268669T3 (da) 2017-11-20
US20130164302A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
AU2009222965B2 (en) Immuno-modulating compositions for the treatment of immune-mediated disorders
US20190209681A1 (en) Anti-LPS Enriched Immunoglobulin Preparation for Use in the Treatment and/or Prophylaxis of a Pathologic Disorder
DK2605791T3 (en) ANTI-LPS ENHANCED IMMUNOGLOBULIN PREPARATION FOR USE IN TREATMENT AND / OR PROPHYLAXY OF A PATHOLOGICAL DISORDER
KR20080107050A (ko) 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
EP2465528A2 (fr) Cellules NKT élevées et leurs utilisations dans le traitement de troubles liés à l'immunité
US20140255403A1 (en) Oral composition comprising a tnf antagonist and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09720973

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2718381

Country of ref document: CA

Ref document number: 587901

Country of ref document: NZ

Ref document number: 2009222965

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009222965

Country of ref document: AU

Date of ref document: 20090311

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2009720973

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009720973

Country of ref document: EP